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ABBREVIATIONS 
°C Degree Celsius 
a.u. Arbitrary units 
C-terminus carboxy terminus 
CA Cell array 
Cbl Casitas B-lineage lymphoma proto-oncogene 
cDNA complementary DNA 
DMEM Dulbecco´s modified Eagle´s medium 
DNA deoxyribnucleic acid 
dNTPs deoxyribonucleoside triphosphates 
EDTA ethylenediamininetetraacetic acid 
EGF Epidermal growth factor 
EGFR Epidermal growth factor receptor 
ER endoplasmatic reticulum 
FERM 4.1 protein ezrin radixin moesin 
FLIM Fluorecence liftime imaging microscopy 
FRET Förster resonance energy transfer 
GFP green fluorecent protien 
HEPES 
N-2-hydroxyethylpiperanzine-N´-2-ethanesulfonic- 
acid 
Hz hertz 
MCF7 Michigan cancer foundation 7 
 5 
min minutes 
mTFP monomeric teal fluorescent protein 
NADP Nicotinamide adenine dinucleotide phosphate 
NLS nuclear localization sequence  
NM Nuclear membrane  
NOX NADPH oxidase 
NRPTP non-receptor PTP 
ns nanosecond 
PM plasma membrane 
PTB phosphotyrosine binding 
PTP protein tyrosine phosphatase  
pY phosphotyrosine 
RNA Ribonucleic acid 
ROS reactive oxygen species  
RPTP receptor-like protein tyrosine phosphatase 
RT room temperature 
RTK receptor tyrosine kinase 
SH2 src homology 2 
siRNA small interfering RNA 
Src Proto-oncogene tyrosine-protein kinase Src 
TM transmembrane  
WT wild type 
µl microliter 
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ABSTRACT 
Autocatalytic activation of Epidermal Growth Factor Receptor (EGFR) at the plasma 
membrane increases the sensitivity of the cell to extracellular growth factors but can also 
generate spontaneous receptor activation in the absence of stimulation. As a mechanism to 
control EGFR phosphorylation at the plasma membrane, receptor endocytosis and vesicular 
trafficking relocalizes activated, phosphorylated EGFR to perinuclear compartments rich in 
Protein Tyrosine Phosphatases (PTPs), such as PTPN1, which dephosphorylate and 
inactivate the receptor. Although the role of few PTPs in regulating EGFR phosphorylation 
is known, it is unclear how PTPs that are spatially segregated in distinct cellular 
compartments, modulate EGFR autocatalytic activation and hence its downstream signaling. 
Through quantitative imaging of EGFR phosphorylation upon genetic perturbations of 
classical PTPs and EGFR-PTP interactions, we identified endoplasmic reticulum (ER) 
associated PTPN2 and plasma membrane associated receptor-like PTPRG/J as strong, direct 
negative regulators of EGFR. Using single cell measurements of phosphorylation of the 
EGFR downstream signaling tyrosine residue Y1068, we generated a spatial-temporal 
reactivity map to identify local phosphatase activity. By negatively regulating EGFR 
phosphorylation, we deduced the role of PTPN2/PTPRJ in determining signal duration: a 
function that is coupled to vesicular trafficking.  Furthermore, by maintaining the plasma 
membrane density of EGFR due to its interaction with ligandless EGFR and 
dephosphorylation of EGFR at Y1045 - a cCbl-ubiquitin ligase binding site, PTPN2 
participates in a spatially established negative-feedback that is mediated by vesicular 
recycling.  Through its activity on ligandless EGFR at plasma membrane, PTPRG regulates 
the autocatalytic activity of EGFR and influences the responsiveness of a cell to EGF dose. 
Altogether our findings indicate that by spatially segregating PTPs with different functional 
relationships to EGFR, the cell is able to sense and respond to its environment. 
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ZUSAMMENFASSUNG 
Autokatalytische Aktivierung des epidermalen Wachstumsfaktor-Rezeptors (EGFR) an der 
Plasmamembran erhöht die Sensitivität der Zelle gegen gegenüber extrazellulären 
Wachstumsfaktoren, kann jedoch gleichzeitig auch spontane Aktivierung des Rezeptors in 
Abwesenheit eines Liganden erzeugen. Ein Mechanismus die Phosphorylierung von 
aktivierten EGFR an der Plasmamembran zu kontrollieren beinhaltet Rezeptor-Endozytose 
und vesikulärer Transport des Rezeptors durch perinukleäre Kompartimente welche eine 
hohe Konzentration an Protein Tyrosin Phosphatasen (z.B. PTPN1) aufweisen und den 
Rezeptor durch Dephosphorylierung inaktivieren. Bisher ist nur von wenigen PTPs die Rolle 
bei der Regulation der EGFR-Phosphorylierung bekannt, weiterhin ist es unklar, wie PTPs, 
die in verschiedenen zellulären Kompartimenten räumlich getrennt sind, die 
autokatalytische EGFR-Aktivierung und Signalweiterleitung modulieren. Durch 
quantitative Mikroskopie der Phosphorylierung von EGFR in Kombination mit genetischen 
Störungen klassischer PTPs und EGFR-PTP-Interaktionen wurden die mit dem 
endoplasmatischen Retikulum (ER) assoziierte Phosphatase PTPN2 und die 
Plasmamembran-assoziierten, Rezeptor-ähnlichen Phosphatasen PTPRG/J als starke, 
direkte Regulatoren von EGFR identifiziert. Mittels Einzelzellmessungen der 
Phosphorylierung des EGFR-Downstream-Signaltyrosinrests Y1068 wurden räumlich-
zeitliche Reaktivitätskarten um die lokale Phosphatase-Aktivität zu bestimmen. Hierbei 
wurde eine an vesikuläreren Transport gekoppelte negative regulatorische Funktion von 
PTPN2/PTPRJ abgeleitet, welche die Dauer der Signalweiterleitung bestimmt. Weiterhin 
wurde gezeigt, das PTPN2 durch Interaktion mit ligandenfreiem EGFR und De-
phosphorylierung der Bindestelle (Y1045) der Ubiquitin-Ligase cCbl die Dichte von EGFR 
an der Plasmamembran mittels vesikuläreren Transport reguliert. Durch Interaktion mit 
ligandenfreiem EGFR an der Plasmamembran reguliert PTPRG die autokatalytische 
Aktivität von EGFR und beeinflusst so die Reaktivität der Zelle gegenüber verschiedenen 
EGF Konzentrationen. Zusammenfassend zeigen diese Ergebnisse, dass durch räumliche 
Trennung von PTPs mit unterschiedlichen funktionellen Beziehungen zu EGFR die Zelle in 
der Lage ist, ihre Umgebung zu erkennen und darauf zu reagieren. 
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INTRODUCTION 
 
1.1 CELL SIGNALING 
A cell senses extracellular cues through its respective receptors present on its plasma 
membrane. Depending upon the strength of this stimuli, which is a reflection of the 
concentration of the chemical cue, the receptors are activated, in most cases leading to a 
conformational change that elevates their enzymatic activity(Lemmon and Schlessinger, 
2010; Reynolds et al., 2003). The most common receptors are protein based tyrosine kinases 
that phosphorylate the tyrosine residues of their substrate (Figure 1-1)(Arkhipov et al., 2013; 
Kovacs et al., 2015). The activated receptor allows the cell to transmit an active signal 
through modification of various other spatially distributed downstream signaling proteins. 
The flow of such a signaling cascade is terminated when the activated protein is degraded or 
Figure 1-1 Schematic representing protein tyrosine phosphorylation-dephosphorylation cycle. PDB ID: 
4G5J 
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is deactivated by a class of proteins called phosphatases (Haj, 2002; Tao et al., 2001). The 
conventional thought of perceiving signaling tracks as a linear pathway has been challenged 
due to the presence of recurring regulatory or feedback circuits between different signaling 
components. The spatial-temporal dynamics of signaling network, therefore, helps 
maintaining homeostasis or facilitates adaptation to a new environment.  
Until the first discovery of the tyrosine kinase v-Src by Prof Ray Erikson, which was later 
characterized by Prof Tony Hunter for its role in tyrosine residues phosphorylation in 
proteins, the importance of the phosphorylation-dephosphorylation cycle was limited to the 
metabolism (Gschwind et al., 2004; Hunter and Cooper, 1985; Robinson et al., 2000; 
Ségaliny et al., 2015). Protein-tyrosine kinases (PTKs) are known to phosphorylate tyrosine 
residues of their protein substrate by transferring gamma phosphate of ATP (Figure 1-1). It 
was the discovery of various other tyrosine kinases like INSR, JAKs, STAT and MAPKs, in 
the 1990s that started to fill the gaps in the knowledge of the protein kinase cascades and 
their role in regulating cellular function. Sequencing of the human genome lead to the 
identification of 90 active TK genes; out of which 58 encode receptor TKs and 32 genes for 
non-receptor TKs(Robinson et al., 2000). Tyrosine kinases participate and monitor various 
cellular functions and the fact that they form a major fraction of all the known oncogenes 
makes understanding their role even more important (Regad, 2015; Robinson et al., 2000). 
1.2 EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR)   
EGFR is a member of ERBB family of RTKs and was among the first RTKs to be 
discovered. The EGF mediated activation of this protein intrigued the biochemists about its 
possible substrates and their role in cells (Ferguson, 2008). It was observed that this protein 
primarily acts as a substrate to its own enzymatic activity(Lemmon and Schlessinger, 2010). 
The fact that EGFR gets internalized upon EGF stimulation highlighted the possible role of 
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energy invested vesicular trafficking in signaling contrary to a simple diffusion-based model. 
Unravelling of the structure and the mechanisms of activation, identification of signaling 
adaptor proteins containing Src Homlogy 2 (SH2) and phosphor-tyrosine binding (PTB) 
domains, identification of the vesicular trafficking entities and discovery of first tyrosine 
phosphatase PTP1B translated our understanding of EGFR activity(Tonks, 2005). 
1.2.1 THE STRUCTURE OF EGFR SHOWS REGULATION AT DIFFERENT SITES 
Due to the difficulty in getting a crystal of an intact EGFR full length protein, the knowledge 
we have today about its structure are from NMR and X-ray data obtained from either external 
regions or internal parts. The EGFR monomer consists of an extracellular region, 
transmembrane domain, juxtamembrane region, a kinase domain and a C-terminal tail with 
regulatory tyrosine sites (Figure 1-2A). 
EXTERNAL DOMAIN: The external region comprises of four domains. The EGF binding 
pocket is formed by Domain I and Domain III and two cysteine rich domains Domain II and 
Domain IV(Klein et al., 2004). In the absence of ligand, the interaction of Domain II with 
Domain IV leads to a closed conformation of the EGFR monomer(Ferguson, 2008; Ogiso et 
al., 2002). Upon ligand binding to Domain I and Domain III, there is a structural 
rearrangement that exposes the dimerization arm in Domain II that can interact with other 
receptors to form a dimer. Domain IV plays a role in altering the binding affinity towards 
EGF or in mediating the higher oligomerization states of EGFR. As a dimer, one EGFR 
molecule interacts with other EGFR molecule in a back-to-back conformation through the 
dimerization arm making this a receptor mediated interaction rather than ligand mediated 
(Gan et al., 2007)(Figure 1-2B). 
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TRANSMEMEBRANE-JUXTAMEMBRANE REGION: The juxta-membrane region of EGFR has 
an auto-inhibitory role that entraps the monomeric EGFR in an inactive state(Shan et al., 
2012). The conformational change induced due to ligand binding releases this auto-
inhibition, affecting the orientation of JM-TM in the formation of dimeric EGFR, now, in 
an active state. Although the monomeric form of EGFR was always considered to be an 
inactive state, this does not imply that the kinase activity of EGFR is shut down. Recent 
studies have shown that even in a monomeric state, EGFR has a weak kinase activity that 
facilitates lower amplitude downstream signaling in the absence of a ligand(Baumdick et al., 
2015). It has also been reported that the phosphorylation of the threonine residues of EGFR 
Figure 1-2 A) Schematic representation of the EGFR structure. A single transmembrane domain 
connects the extracellular ligand-binding domain with the cytosolic part of EGFR. The cytosolic domain is 
further separated to the juxtamembrane segment, the tyrosine kinase domain with the aC-helix and 
activation loop, and the C-terminal tail with several tyrosine residues. Mechanism of EGFR activation. B) 
Ligand binding to EGFR results in the formation of an asymmetric dimer, where one receptor acts as an 
‘activator’ and the second one as a ‘receiver’. Tyrosine phosphorylation at the C tail of the ‘receiver’ kinase 
can only occur if the receptors dynamically change their positions (Adapted from Jura et al., 2009). 
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(T654/T669) in the juxta-membrane by ERK affects the oligomerization step and maintains 
EGF-EGFR molecules in the monomeric state(Kluba et al., 2015).  
KINASE DOMAIN: The EGFR kinase domain comprises of two lobes: C-lobe and N lobe. The 
C-lobe (activator) of one EGFR molecule interacts with the N-lobe (the receiver) of the 
kinase domain of the binding partner kinase. This interaction leads to the formation of an 
asymmetric dimer. This stabilizes the EGF mediated allosterically activated conformation 
of the receiver kinase domain. The kinase domain also contains the lysine residues that act 
as a substrate to ubiquitin ligases like cCBL which controls affects ubiquitination and thus 
tags EGFR for endosomal sorting. The structural and molecular dynamics simulations 
suggested that Y845 phosphorylation in the activation loop suppresses the intrinsic disorder 
in the aC-helix, thereby stabilizing the active conformation (Shan et al., 2012). If this active 
conformation would further catalyze Y845 phosphorylation on other EGFR molecules 
thereby further stabilizing EGFR molecules in an active conformation this would provide 
the basis for autocatalytic amplification of EGFR activity (Reynolds et al., 2003; Tischer 
and Bastiaens, 2003).  
EGFR C-TERMINAL TAIL: At the C terminal end, EGFR consists of a 229aa peptide that 
harbors autophosphorylation tyrosine sites with signaling and trafficking potential. 
Phosphorylation of Y845 avails autocatalytic function to EGFR that plays an important role 
in the lateral signal propagation. The mechanism by which pY845 is able to carry out this 
function has not been shown experimentally but simulation data indicates that it might be 
due to its capability to suppresses the intrinsic disorder of EGFR. Ligand induced 
autophosphorylation of Y992, Y1068, Y1086, Y1148, and Y1173 acts as a docking sites for 
adapter proteins like Grb2 and Shc to trigger downstream signaling. In addition to EGFR 
bound Grb2, E3 ubiquitin ligase c-Cbl also binds to pY1045 of EGFR.  
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1.2.2 EGFR DOWNSTREAM SIGNALING  
Activation of EGFR might lead to different cellular fates like survival, proliferation or 
apoptosis. Proteins with SH2 or PTB domain typically recognize a pTyr residue orchestrated 
by a specific amino acid sequence(Wagner et al., 2013). Their recruitment to these sites 
stimulate recruitment of other proteins and assembling of complexes that result in activation 
of the downstream signaling proteins. Upon phosphorylation of pY1068 /pY1086 of EGFR, 
Grb2 binds to these sites due to its SH2 domains(Sorkin et al., 2000). Through its SH3 
domains, GRB2 is bound to SOS (Son of Sevenless), which is thus recruited to the plasma 
membrane. The increased proximity of SOS to membrane bound RAS results in increased 
nucleotide exchange on Ras (Wee and Wang, 2017). The GTP bound RAS now 
phosphorylate Raf kinase that in turn activates ERK in a MEK dependent manner(Fey et al., 
2016). An active cytoplasmic ERK shuttles to the nucleus and increase the transcription of 
cFOS. The other major downstream protein that is activates through EGFR is AKT(Gan et 
Figure 1-3 Schematic showing an overview about the major downstream signaling initiated by auto 
phosphorylation of EGFR tyrosine sites shown in orange. The figure has been adapted from (Morandell et al., 
2008). 
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al., 2010). Involvement of EGFR pY1173 bound Shc protein in activating AKT is arguable, 
the commonly accepted mechanism is via a Grb2-Gab1 complex(Keilhack et al., 1998). 
PI3K is recruited and activated on the cell membrane by interacting with phosphorylated 
Gab. PI3K converts PIP2 to PIP3 which then acts as a binding partner for both AKT and its 
activator PDK(Wee and Wang, 2017). PDK phosphorylates T308 of the AKT while the S473 
is phosphorylated by mTOR(Nishimura et al., 2015). The role of Grb2 in mediating both 
AKT and ERK signals indicates that the signaling does not follow a fixed pathway. The 
activation state of EGFR, magnitude of its phosphorylation, spatial distribution and 
availability of the accessory proteins collectively determines the signaling outcome.   
A sustained ERK response leads to activation of cFOS and further increases its expression. 
cFOS is a transcription factor that increases expression of other proliferation associated 
gene(Wu et al., 2012)s. A transient ERK response, however, activates less amount of cFOS 
which is degraded immediately. This demonstrates that the cellular decision depends on the 
temporal response profile of an RTK and their downstream signaling proteins, and thus 
regulation of these profiles becomes an important mechanism. EGFR is known to be 
regulated by two mechanisms; Either it is degraded in the lysosome which affects the total 
concentration in the cell or it is dephosphorylated by protein tyrosine phosphatases which 
affects the activity. Both of these mechanisms are highly dependent on the vesicular 
trafficking system of a cell. 
1.3 EGFR REGULATION BY VESICULAR TRAFFICKING 
The two common mechanism of EGFR internalization is mediated by Clathrin coated 
vesicles or Caveolae rafts mediated vesicles(Mayor et al., 2017) (Figure 1-4). Although, both 
of these mechanisms are dependent on receptor ubiquitination their role in receptor sorting 
and signaling is still unclear. The receptor vesicles are then converged to the early endosome. 
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The early endosome acts as a distributing hub wherein Rab5-positive vesicles mature into 
Rab7-late endosomes, which are then fused to the lysosome that contains proteolytic 
Figure 1-4 Vesicular trafficking of EGFR upon EGF stimulation. Ligand-bound EGFR is internalized 
and either recycled back to the PM via peripheral or pericentriolar recycling or targeted to lysosomes 
for degradation. The indicated Rab GTPases are specific for the different endosomal compartments and 
involved in endosomal fusion and fission events. Magenta-endosomal protein, Red-signaling protein 
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enzymes that degrades the EGFR signaling complex(Bucci et al., 1992; Rink et al., 2005). 
Ubiquitination mediated by cCbl is important to provide directionality to these vesicles to 
mature into the late endosomes(Ravid et al., 2004). A polyubiquitinated molecule is immune 
towards the activity of deubiquitinating enzymes (DUBs) present in the endosomal-sorting 
complexes required for transport (ESCRT) in the early endosomes(Millard and Wood, 
2006). The de-ubiquitinated EGFR molecules are recycled back to the plasma membrane by 
Rab4 (fast recycling) or through perinuclear localized Rab11 positive endosomes (slow 
recycling) (Mohrmann et al., 2002; Ullrich et al., 1996).   
Apart from endosomal sorting, presence of Rab7 positive late endosomes and Rab11 positive 
recycling endosomes in the phosphatase-rich perinuclear region plays an important role in 
spatial-temporal regulation of EGFR signaling. It has been shown that autonomously 
activated and ligand activated EGFR molecules employs different trafficking machinery.  In 
absence of an external stimuli, spontaneous autocatalytic activation of receptors at the 
plasma membrane gets internalized and are recycled back after dephosphorylation at the 
recycling endosomes. Therefore, the primary function of EGFR recycling is to suppress 
spontaneous phosphorylation of Y845 that leads to autocatalysis. As the recycled species are 
predominantly monomeric, recycling of the receptor also maintains a specific receptor 
concentration at the plasma membrane allowing the cell to respond to ligand stimulation. 
Ligand activated EGFR molecules, on the other hand, gets ubiquitinated upon 
phosphorylation of tyrosine 1045 (Baumdick et al., 2015)and travels in unidirectional way 
to lysosomes through perinuclear region with high PTPN1/PTPN2 activity. As ligand 
binding stabilizes active conformation of EGFR that leads into sustained downstream 
signaling, unidirectional trafficking plays a major role in determining signal duration.  
1.4 EGFR REGULATION BY DEPHOSPHORYLATION 
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As ubiquination is directly dependent on phosphorylation of the tyrosine residues on EGFR 
to which cCbl binds, directly or via Grb2, dephosphorylation of these residues emerges as 
an important mechanism that affect EGFR trafficking(Grovdal et al., 2004; Parks and 
Ceresa, 2014). Similarly, the kinase activity as well as downstream signaling is affected 
Figure 1-5 A) Structure of all the classical PTPs (Tonks, 2006). B) Representation of the catalytic 
domain of PTPN1 (Andersen et al., 2001) and B) details of different structural, catalytic and regulatory 
motif. 
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upon dephosphorylation of autocatalytic and signaling tyrosine residues, respectively. 
Dephosphorylation of pTyr residues of EGFR is carried out by a class of protein tyrosine 
phosphatase (PTP). There are 107 PTPs classified into different classes based on their 
homology in their PTP catalytic domain sequence(Andersen et al., 2001; Tonks, 2006). 
Classical PTPs are further classified as transmembrane receptor PTPs and non-
transmembrane cytosolic PTPs (Figure 1-5). 
Their differential activity on EGFR is an outcome of their enzymatic ability arising by their 
regulatory domain and oxidative potential of their compartment. Although the localization 
motif has no direct effect on the catalytic activity of the PTPs, which is confined to the active 
PTP domain, it controls the concentration in distinct spatial compartments and thus has an 
indirect effect on the role of the PTPs(Yang et al., 2007). 
1.4.1 THE PTP DOMAIN HAS HIGHLY CONSERVED MOTIFS 
Apart from having an extra-cellular domain, a transmembrane domain and active PTP 
domain, few of the receptor-PTPs have an additional catalytically inactive PTP domain that 
is mostly involved in regulating in PTP activity. Some of the cytosolic PTPs, on the other 
hand, have adaptor domains like SH2, PEST in addition to a localization sequence.  
PTP DOMAIN 
Upon sequence alignment of the PTP domains, ten conserved motifs obtained from PTP1B 
sequence were identified. (M1 to M10, Table 1-1).  
Structural motifs (M2-M7): The hydrophobic segments assist in efficient packing of the 
protein structure assisting in its conformational stability.  
Functional motifs (M1, M8-M10): PTP signature motif sequence (M9) present is involved 
in binding to the phosphate molecule of the substrate via the cysteine residue (a nucleophile). 
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The Arg and Ser residue in this motif are involved in stabilizing the thiolate form of the 
cysteine. With aromatic and non-polar amino acids in the sequence, M1 is involved in 
recognizing phosphotyrosine residues. As the sequence of the M1 motif is highly conserved 
among different PTPs (Table 1-1), it indicates a similar mechanism of substrate recognition. 
  
Table 1-1 Details of different structural, catalytic and regulatory motif along with their 
sequences. 
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The substrate binding leads to conformational changes that bring the WPD loop present in 
M8 close to the tyrosyl substrate and allows Asp (as a general acid catalyst) to donate a 
proton to the phenolate group. The Gln in M10 or catalytic-water motif assists in the second 
hydrolysis step of the phosphocysteine enzyme complex(Andersen et al., 2001). 
OTHER DOMAINS 
The extracellular domain of many RPTPs are involved in a cell-cell interaction due to 
presence of Fibronectin type III-like, Meprin-A5 or Carbonic anhydrase like domains 
(Figure 1-5A). PTPRA and PTPRE are glycosylated at their N terminal which assists in their 
membrane localization(Tonks, 2006). Cytosolic PTPs, PTPN6/PTP11 and PTPN5/PTPN7, 
have the SH2 and KIM domain respectively that regulate their phosphatase activity(José et 
Figure 1-6 Schematic showing mechanism of Cys215 (PTPN1) mediated 
dephosphorylation of pTyr (Top) and reversible oxidation due to reactive oxygen species 
(Bottom) (Tonks, 2006)  
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al., 2003; Tenev et al., 1997). The FERM domain present in PTPN14 and PTPN21 mainly 
interacts with the endosomal proteins implying a possible function of these PTPs in 
endocytosis(Belle et al., 2015; Roda-Navarro and Bastiaens, 2014). PEST domain present 
in PTPN12 allows its substrate to be subjected to K3 proteasomal degradation; while the 
additional PTP domain in R-PTPs participates in regulating the phosphatase activity in an 
oxidizing environment(Yang et al., 2007). 
1.4.2 REGULATION 
The SH2 domain, both in PTPN6 and PTPN11 interacts with the PTP domain and traps the 
protein in an auto-inhibited conformation(Sun et al., 2013). When the SH2 domain interacts 
with pTyr of an activated RTK, this releases the auto inhibition and elevates their 
phosphatase activity. Therefore, the dependency of these PTPs on their substrate for their 
activity is necessary in tuning EGFR activity. KIM domain of PTPN5/PTPN7 follows a 
similar mechanism with ERK as an interacting-activating partner(José et al., 2003). 
The lower pKa value of the cysteine present in the PTP catalytic site makes it susceptible to 
oxidation(Weibrecht et al., 2007). Oxidative reactions occur mainly due to generation of 
reactive oxygen species (O2- or H2O2) by NOX complex triggered as a response to a stress 
or growth factor stimulation(Bánfi et al., 2003). Upon oxidation, the thiolate form of cysteine 
in the PTP loop is converted into sulfenic acid (intermediate) and is oxidized to 
sulfenamides(Ross et al., 2007). The sulfenic acid form of cysteine of the adjacent proteins 
can form a disulfide bond. Both sulfonamides and disulfide bonds can be readily reduced to 
thiols by the thioredoxin or glutathione-dependent systems. Depending upon the oxidative 
potential, the cysteine residue can also be irreversibly oxidized to sulfinic acids, 
sulfinamides, sulfonic acids or sulfonamides(Tanner et al., 2011).  
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Phosphorylation has also been pointed to be one of an important mechanism of PTP 
regulation. Tyr798 of PTPRA upon phosphorylation can act as a hub for Grb2 binding which 
might help in its internalization. The SH2 domain of SHP2 (upon phosphorylation of Tyr 
residues at the C terminal tail of SHP2) also acts a binding site for Grb2 which is necessary 
to maintain the SHP2 in an open conformation(Sun et al., 2013). 
1.5 INTERPLAY BETWEEN EGFR AND PTP ACTIVITY 
Previously, many screening experiments have been reported that presented PTPs as 
regulators of EGFR. A set of purified PTP proteins were screened for their activity on a 
peptide with an important pTyr residue specific to a particular RTK(Barr et al., 2009). These 
experiments showed that the EGFR pY1068 was a substrate for PTPN1, PTPN2, PTPN5, 
Figure 1- 7 Scatter plot of median EGFR phosphorylation fold-changes (𝑷𝑭𝑪𝜶 = 𝛂𝑷𝑻𝑷 𝛂𝒄𝒕𝒓+ , 
n~150 cells per condition) upon siRNA-knockdown (𝑷𝑭𝑪𝜶-siRNA) and ectopic PTPX-mCitrine 
expression (𝑷𝑭𝑪𝜶-cDNA), 5min after 200ng/ml EGF stimulation. Significant 𝑷𝑭𝑪𝜶 upon both 
(red dots) or only one perturbation (green/blue lines, p<0.05) are shown. Marker length scaled to 
relative MCF7 PTPX-mRNA levels. 
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PTPN9, PTPRA, PTPRB, PTPRC, PTPRE, PTPRG, PTPRJ and PTPRO. Among these, 
PTPRJ showed highest phosphatase activity. Another study with siRNA mediated PTP 
knockdown in MCF7 cells showed that PTPRJ and PTPRK act as negative regulators of 
EGFR(Tarcic et al., 2009). A recent PTP-EGFR interaction study, with a membrane two 
hybrid screen for Non-receptor PTPs and mammalian membrane two hybrid screen for 
Receptor PTPs, showed PTPN6, PTPN7, PTPN11, PTPN12, PTPRA, PTPRB, PTPRE, 
PTPRG, PTPRH, PTPRK, PTPRS, PTPRT, PTPRU and PTPRZ as interacting partner of 
EGFR(Yao et al., 2017). The same study also evaluated phosphatase activity of PTPRA, 
PTPRH and PTPRB towards EGFR.  
Several PTPs were identified by cell array fluorescence lifetime imaging microscopy (CA-
FLIM) to regulate ligand activated EGFR (Thesis-Fengler, 2014). siRNA mediated knock 
down or ectopic cDNA-mCitrine expression PTP in MCF7 cells with, identified PTPRG, 
PTPRA, PTPRJ, DUSP3 and PTPN2 as non-redundant negative regulators of EGFR. 
PTPN1, PTPN9 and PTPRE were identified as negative regulator of EGFR only in cDNA 
perturbation indicating that their activity might be redundant to other endogenous PTPs 
present in MCF7 cells. Other classical PTPs like PTPN5, PTPN6, PTPN14, PTPRF and 
PTPRR were identified in the siRNA screen implying either these proteins are regulated or 
they act on EGFR at later time points.  
The phosphatase to kinase activity determines the phosphorylated state of EGFR. At the 
plasma membrane, PTP inhibition is coupled to the RTK activity via ROS generation 
(Reynolds et al., 2003). This double negative feedback topology between EGFR and PTP at 
the plasma membrane creates a bistable system (Reynolds et al., 2003). In general, a bistable 
system can switch between two distinct stable states. An EGF dosage that is able to bring 
the system above the bistable regime, can do so due to EGFR autocatalytic function 
attributed to pY845 phosphorylation coupled to PTP inhibition by ROS. With time, 
 24 
internalized phosphorylated EGFR molecules encounter ER-PTPs with high phosphatase 
activity. This vesicular trafficking mediated negative feedback interaction brings down the 
total amount of phosphorylated EGFR and leads into shut down of the RTK signaling. 
Although few PTPs have been identified as regulators of EGFR, the mechanism of regulation 
is still not clear. Characterizing the strength of each PTP activity on EGFR at different time 
point and determining if the regulation is direct or indirect will expand our understanding 
about PTP functionality. Phosphorylation at Y1045 of liganded EGFR causes ubiquitination 
and internalization leading it to lysosomes for degradation. With low degree of 
Figure 1-8 A) Schematic representation of the RTK – PTP network topology 
exemplifies a double negative feedback loop. Together with the autocatalytic activity 
of RTKs generates a bistable system. The fraction of phosphorylated RTK (RTKp) at 
steady state as function of the relative maximal PTP/RTK activity (P/K). Stable steady 
states (green line-resting; red line-activated), blue lines-unstable saddle point. Where 
the red and green lines coincide, the system is bistable (Reynolds et al., 2003) B) A 
negative feedback RTK–PTP interaction results in a single dynamical solution 
implying this interaction might play role in signal duration (Koseska and Bastiaens, 
2017). 
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ubiquitination, monomeric EGFR is brought back to the plasma membrane through Rab11 
recycling endosomes. The monomeric EGFR at the plasma membrane is able to maintain 
the responsiveness of a cell to varying EGF concentration, while liganded EGFR is mainly 
involved in downstream signaling via pY1068. How spatially distributed PTPs affect Y1045 
and Y1068 phosphorylation will attribute to our understanding about how different PTPs 
affect EGFR response.  
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OBJECTIVES 
 
In many cancer cells, elevated RTK activity results from loss or suppression of negative 
regulators i.e protein tyrosine phosphatase (PTP). Previous studies have shown that 
autocatalytic RTK activation is coupled to local PTP inhibition, thereby generating a bistable 
system exhibiting switch-like response properties (Reynolds et al., 2003;). Activated 
receptor molecules at the plasma membrane are rapidly endocytosed and traffic from early 
to late endosomes towards the lysosome. During vesicular trafficking, they interact with 
perinuclear-localized PTPs (e.g. PTPN1, which dephosphorylate activated receptors and 
thereby cease downstream signaling events. Although the significance of PTPs modulating 
EGFR activity and signaling has been described in numerous studies, it is still unclear how 
spatially segregated PTPs collectively regulate EGFR activity. Large-scale and individual 
studies have identified PTPs that regulate EGFR phosphorylation (Barr et al., 2009; Liu and 
Chernoff, 1997; Tarcic et al., 2009; Tiganis et al., 1998; Yao et al., 2017; Yuan et al., 2010). 
However, the functional role of individual spatially segregated PTPs in controlling the 
phosphorylation dynamics of EGFR remains unknown. In this thesis, quantitative imaging 
of EGFR phosphorylation in response to genetic perturbations of PTPs is employed to 
characterize the strength of the phosphatase activity of all PTPs which were identified as 
negative regulators during a reciprocal perturbation- CA-FLIM screen (Figure 1.7). By 
creating a library of PTP substrate-trapping mutants, we want to identify which PTPs are 
direct regulators of EGFR activity. With higher resolution microscopy techniques and single 
cell analysis, we aim to decompose the phosphorylation/dephosphorylation cycle of EGFR 
pY1068–Grb2 binding site, in space and time and create a spatial-temporal PTP reactivity 
map By determining the interaction and reactivity of PTPs over pre-stimulated and post 5P-
EGF stimulated EGFR molecules, we want to identify PTPs that determine responsiveness 
of a cell to EGF stimuli and those that regulate signal duration. 
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MATERIALS 
 
2.1.1 CHEMICAL 
Chemical Manufacturer 
2-Mercapto-ethanol SERVA Electrophoresis GmbH 
Acetic acid Sigma-Aldrich 
Ammonium persulfate (APS) SERVA Electrophoresis GmbH 
Ampicillin sodium salt SERVA Electrophoresis GmbH 
Bromophenolblue Sigma-Aldrich 
Copper(II) Sulfate (CuSO4) Sigma-Aldrich 
Dimethyl sulfoxide (DMSO) SERVA Electrophoresis GmbH 
Dithiothreitol (DTT) Fluka Analytical 
Ethanol J.T.Baker 
Ethylenediaminetetracetic acid (EDTA) Fluka® Analytical 
Glycerol GERBU Biotechnik GmbH 
Hoechst 33342 Thermo Fisher Scientific 
Isopropanol J.T.Baker 
Kanamycin sulfate GERBU Biotechnik GmbH 
Magnesium chloride (MgCl2) Merck KG/J.T.Baker 
Methanol AppliChem GmbH 
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N,N,N’,N’-Tetramethylene-diamine (TEMED) Sigma-Aldrich 
Sodium chloride (NaCl) Fluka Analytical 
Sodium dodecyl sulfate (SDS) SERVA Electrophoresis GmbH 
Tris-base Carl Roth GmbH 
Tris-HCl J.T.Baker 
Tritox X-100 SERVA Electrophoresis GmbH 
Tween 20 SERVA Electrophoresis GmbH 
UltraPure™ Agarose Thermo Fisher Scientific 
 
2.1.2 EQUIPMENT 
Centrifuge 5417 R (Eppendorf), Centrifuge 5810 R (Eppendorf), Concentrator plus (Eppendorf), 
Spectrophotometer (Beckman coulter), Master cycler (Eppendorf), Multiskan Ascent (Thermo E.C), Nanodrop 
ND-1000 (PeqLab), Gel Doc XR System (BioRad), Safe Imager (Invitrogen), Odyssey scanner (LiCor), Power 
Pac 300 (BioRad), Power Pac HC (BioRad), Vortexer (Scientific Industries), CO2 Incubator (IBS Integra), 
Biological safety cabinet (IBS Integra) 
 
2.1.3 MEDIA  
 Components 
LB Media 10 g/l Bacto-Tryptone, 10 g/l Sodium chloride, 5 g/l Bacto-
yeast extract 
LB Media with Ampicillin 10 g/l Bacto-Tryptone, 10 g/l Sodium chloride, 5 g/l Bacto-
yeast extract, 100 mg/l Ampicillin 
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LB Media plates with Ampicillin 10 g/l Bacto-Tryptone, 10 g/l Sodium chloride, 5 g/l Bacto-
yeast extract, 100 mg/l Ampicillin, 1.5% Bacto-agar 
TB Media 12 g/l  Tryptone, 24 g/l Yeast Extract, 4 ml/l Glycerine, 0.17 M 
Monopotassium phosphate, 0.72 M Dipotassium phosphate 
TB Media with Ampicillin 12 g/l  Tryptone, 24 g/l Yeast Extract, 4 ml/l Glycerine, 0.17 M 
Monopotassium phosphate, 0.72 M Dipotassium phosphate, 
100 mg/l Ampicillin 
SOC Media 20 g/l Bacto-Tryptone, 5 g/l Yeast Extract, 0.58 g/l NaCl, 0.19 
g/l CaCl2, 2.03 g/l MgCl2,6H2O, MgSO4, 7H2O, 2 % Glucose 
 
COMMERCIAL MEDIA - CELL CULTURE 
DMEM (P04-03600, PAN Biotech) with 10 % FBS, 1 % NEAA and 2 mM L-Glutamine (PAN 
Biotech), Non-essential amino acids 100x (PAN Biotech), Imaging media with Hepes (5961214, 
PanBiotech) 
2.1.4 BUFFER 
 Components 
Separating Gel buffer 1 M Tris pH 8.8 
Stacking Gel buffer 0.375 M Tris pH 6.8 
Blotting Transfer Buffer 12 mM Tris, 96 mM Glycine pH 8.3, 20 % Ethanol 
SDS-PAGE Running Buffer 25 mM Tris, 192 mM Glycine, 0.1 % SDS 
TBS 100 mM Tris, 150 mM NaCL pH 7.6 
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COMMERCIAL BUFFERS/SOLUTIONS 
NEB Buffer 2.1 (New England Biolabs), NEB Buffer 3 (New England Biolabs), 10X Lysis Buffer (Cell 
Signaling), Odyssey Blocking Buffer (Li-cor), Big Dye 5 x Buffer (Applied Biosystems), 5X Herculase II 
reaction Buffer (Agilent Technologies), T4 DNA Ligase Buffer (Invitrogen), Nuclease free water (Ambion), 
Premix Big Dye (Applied Biosystems), DPBS (P04-36500, PanBiotech), HistoFix (Roth). 
 
2.1.5 ANTIBODIES 
Goat anti-EGFR (AF231, R&D Systems, rabbit pY1045 (2237, Cell Signaling Technology), rabbit pY1068 
(3777, Cell Signaling Technology), mouse anti-phosphotyrosine (PY72-P172.1, InVivo Biotech Services), 
anti-GAPDH (2118, Cell Signaling), IRDye 800 donkey anti-goat IgG (LI-COR Biosciences), IRDye 680 
donkey anti-rabbit IgG (LI-COR Biosciences), Alexa Fluor® 568 donkey anti-mouse IgG (Life Technologies), 
Alexa Fluor® 568 donkey anti-mouse IgG (Life Technologies) 
 
2.1.6 KITS 
TBST 100 mM Tris, 150 mM NaCL pH 7.6, 0.1 % Tween 20 
5 x SDS sample Buffer 60 mM Tris-HCL ph 6.8, 25 % Glycerol, 2 % SDS, 14.4 mM 
Mercaptoethanol, 0.1 % bromophenolblue 
1 x TAE Buffer 40 mM Tris, 20 mM Acetic acid, 1 mM EDTA pH 8.0 
10 x DNA Gel loading Buffer 5 % Glycerol, 0.01 % OrangeG, 0.1 mM EDTA pH 7.54 
SDS solution 10 % SDS in ddH2O 
Ammonium Persulfate solution 5 % Ammonium persulfate in ddH2O 
PBS-T 0.1 % Triton X100 in PBS (pH7.2) 
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Roti®-Prep Plasmid MINI (Carl Roth GmbH), NucleoBond® Xtra Midi Plus EF (Macherey-Nagel), Micro 
BCATM Protein Assay Kit (Thermo Scientific), ZymocleanTM Gel DNA Recovery Kit (Zymo Research), 
Herculase II Fusion Enzyme with dNTPs combo (Agilent Technologies), BigDye Terminator v1.1 cycle 
sequencing Kit (Applied Biosystems)  
2.1.7 TRANSFECTION REAGENTS 
FuGENE® HD Transfection Reagent (Promega), Lipofectamine® Transfection Reagent (Invitrogen), 
Dharmaffect1 (Dharmacon) 
2.1.8 PLASMIDS AND OLIGOS 
The p2297-OPIN(n)mCitrine (Berrow et al., 2007) and p2150-OPIN(c)mCitrine (Berrow et al., 2007) vectors 
without a His6-Tag were used as a backbone to generate the PTPX–mCitrine library of expression constructs. 
PTPX ORFs were cloned into p2297-OPIN(n)mCitrine or p2150-OPIN(c)mCitrine to obtain constructs with 
mCitrine to their N-terminus or C-terminus respectively. To obtain ORFs from human cell lines, 
mRNA was isolated with the RNeasy Maxi and Oligotex mRNA Midi Kit (QIAGEN) 
followed by cDNA synthesis using the AffinityScript Multiple Temperature cDNA 
Synthesis Kit (Agilent). The cloning of ORF into the pOPIN vector was done with a 
combination of ‘in vivo cloning’ (Oliner	et	al.,	1993) and “sequence and ligase independent 
cloning (SLIC)” (Li	 and	 Elledge,	 2007) by the Dortmund Protein Facility. The primers for 
ligation independent cloning (LIC) were designed with the help of the OligoPerfect primer 
designing and DNAstar lasergene tool of Invitrogen.  
Table 2-1 contains a list of the PTPX constructs along with mRNA reference ID, source of the cDNA/ORF, 
choice of the vector (C or N) and sequence of the Ligation-Independent-Cloning-(LIC) primers. 
2.1.9  BACTERIAL CELL 
Chemical competent XL 10 Gold bacteria cells were used for plasmid propagation.  
2.1.10 MAMMALIAN CELLS 
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MCF 7 (human epithelial adenocarcinoma) were used for all the mammalian cell based studies 
ENZYMES 
Enzyme Company 
BglI New England biolabs 
Herculase II fusion DNA polymerase Agilent Technologies 
T4 DNA Polymerase New england biolabs 
Trypsin/EDTA PanBiotech 
 
2.1.11 DATABASE 
DEPOD, UNIPROT, INSTRUCT were used to obtain information about the structure, localization and 
substrate 
2.1.12 SOFTWARE 
Lasergene DNA star, Matlab, Anaconda, Fiji, Prism, Chimera, Segmentor, EBI align, Expasy translate, 
OligoPerfect™ Designer 
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Gene name expression 
vector 
Source LIC fwr Primer 5' - 3' LIC rev Primer 5' - 3' 
PTPRA p2150-
OPIN(c)mCitri
ne 
cDNA from 
RT-PCR  
TTACAATCAAAGGAGATAT
ACCATGGATTCCTGGTTCA
TTCTTG 
TGAAACAGAACTTCCAGAAA
CTTGAAGTTGGCATAATCTG
AGAAT 
PTPRE p2150-
OPIN(c)mCitri
ne 
Biocat GmbH AGGAGATATACC 
ATGGAGCCCTTGTGTCCAC
TCCTG 
AACAGAACTTCCAGAAATTT
GAAATTAGCATAATCAGAAA
ATATATCAATAAAATCTTGT
ACCACTT 
PTPRF p2150-
OPIN(c)mCitri
ne 
Biocat GmbH TTACAATCAAAGGAGATAT
ACCATGGCCCCTGAGCCAG
C 
TGAAACAGAACTTCCAGAAA
CGTTGCATAGTGGTCAAAGC
TGCC 
PTPRG p2150-
OPIN(c)mCitri
ne 
Biocat GmbH AGGAGATATACC 
ATGCGGAGGTTACTGGAAC
CGTGTTG 
AACAGAACTTCCAGAAACAC
TAGGGACTCCATGCTCTCAG
C 
PTPRJ p2150-
OPIN(c)mCitri
ne 
cDNA from 
RT-PCR  
TTACAATCAAAGGAGATAT
ACCATGAAGCCGGCGGCGC
GGGAG 
TGAAACAGAACTTCCAGAAA
GGCGATGTAACCATTGGTCT
TTCCAAATGTGGTCACGGGC 
PTPN1 p2297-
OPIN(n)mCitri
ne 
Biocat GmbH TGGAAGTTCTGTTTCAGGG
TGAGATGGAAAAGGAGTTC
GAG 
TTAAACTGGTCTAGAAAGCT
TTATGTGTTGCTGTTGAACAG
GAAC 
PTPN14 p2150-
OPIN(c)mCitri
ne 
Biocat GmbH AGGAGATATACC 
ATGCCTTTTGGTCTGAAGC
TCCGCC 
AACAGAACTTCCAGAAAAAT
GAGTCTGGAGTTTTGGAGGA
ACTG 
PTPN2 p2297-
OPIN(n)mCitri
ne 
cDNA from 
RT-PCR  
TGGAAGTTCTGTTTCAGGG
TCCCACCACCATCGAGCGG
GAG 
TTAAACTGGTCTAGAAAGCT
TTATAGGGCATTTTGCTGAA
AAAACAGTGTCCAG 
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PTPN6 p2150-
OPIN(c)mCitri
ne 
cDNA from 
RT-PCR  
TTACAATCAAAGGAGATAT
ACCATGGTGAGGTGGTTTC
ACCGAGACCTCAG 
TGAAACAGAACTTCCAGAAA
CTTCCTCTTGAGGGAACCCTT
GCTC 
DUSP10 p2150-
OPIN(c)mCitri
ne 
Biocat GmbH AGGAGATATACC 
ATGCCTCCGTCTCCTTTAG
ACGACAGG 
AACAGAACTTCCAGAAA 
CACAACCGTCTCCACGCCC 
DUSP7 p2150-
OPIN(c)mCitri
ne 
Biocat GmbH AGGAGATATACC 
ATGCCCTGCAAGAGCGCCG
A 
AACAGAACTTCCAGAAA 
CGTGGACTCCAGCGTATTGA
GTG 
DUSP3 p2150-
OPIN(c)mCitri
ne 
Biocat GmbH AGGAGATATACC 
ATGTCGGGCTCGTTCGAGC
TCT 
AACAGAACTTCCAGAAA 
GGGTTTCAACTTCCCCTCCTT
GG 
EGFR p-mCherry N1 
clontech 
  
EGFR p-mCitrine N1 
clontech 
  
EGFR mTFP    
c-Cbl   TagBFP    
cDNA expression 
vector 
mutation site Mut fwr Primer 5' - 3' Mut rev Primer 5' - 3' 
PTPN1 p2297-
OPIN(n)mCitr
ine 
D181A CTATACCACATGGCCTG
CCTTTGGAGTCCCTGAA
T 
ATTCAGGGACTCCAAAGG
CAGGCCATGTGGTATAG 
PTPN1 p2297-
OPIN(n)mCitr
ine 
C215S GTT GTG GTG CAC AGC 
AGT GCA GGC ATC 
GAT GCC TGC ACT GCT 
GTG CAC CAC AAC 
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PTPN14 p2150-
OPIN(c)mCitr
ine 
D1079A TACTGACTGGCCAGCTC
ACGGCTGTCCAG 
CTGGACAGCCGTGAGCTG
GCCAGTCAGTA 
PTPN2 p2297-
OPIN(n)mCitr
ine 
C216S CCTGCGGTGATCCACAG
TAGTGCAGGCATTG 
CAATGCCTGCACTACTGT
GGATCACCGCAGG 
PTPN2 p2297-
OPIN(n)mCitr
ine 
D182A ATTATACTACCTGGCCA
GCTTTTGGAGTCCCTGA
ATC 
GATTCAGGGACTCCAAAA
GCTGGCCAGGTAGTATAA
T 
PTPN6 p2150-
OPIN(c)mCitr
ine 
C453S CATCATCGTGCACAGCA
GCGCCGGCAT 
ATGCCGGCGCTGCTGTGC
ACGATGATG 
PTPN9 p2150-
OPIN(c)mCitr
ine 
D470A TCTTGAGCTGGCCAGCC
TATGGTGTCCCTTC 
GAAGGGACACCATAGGCT
GGCCAGCTCAAGA 
PTPRA p2150-
OPIN(c)mCitr
ine 
C442S CCATCGTGGTCCACAGC
AGTGCAGGTGTA 
TACACCTGCACTGCTGTG
GACCACGATGG 
PTPRE p2150-
OPIN(c)mCitr
ine 
D250A CAGTACTGGCCCGCCCA
AGGCTGCTGG 
CCAGCAGCCTTGGGCGGG
CCAGTACTG 
PTPRF p2150-
OPIN(c)mCitr
ine 
D1507A CATGGCCTGGCCAGCCC
ATGGAGTTCCTG 
CAGGAACTCCATGGGCTG
GCCAGGCCATG 
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PTPRG p2150-
OPIN(c)mCitr
ine 
C1060S CACACCAGCACTGCTGT
GCACCAACACAG 
CTGTGTTGGTGCACAGCA
GTGCTGGTGTG 
PTPRG p2150-
OPIN(c)mCitr
ine 
D1028A TACACAGTGGCCTGCCA
TGGGAGTTCCCG 
CGGGAACTCCCATGGCAG
GCCACTGTGTA 
PTPRJ p2150-
OPIN(c)mCitr
ine 
D1205A CCTCCTGGCCAGCCCAC
GGTGTTCC 
GGAACACCGTGGGCTGGC
CAGGAGG 
Table 2-1 List of all the plasmids used for different experiments  
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METHOD 
 
2.2.1 GENERATING PTP TRAPPING MUTANTS 
To determine if PTPx directly interacts with EGFR, the catalytic site of PTPs were mutated. The site of 
mutation was chosen on the basis of WPD and XHCSAGXG motif in the active PTP domain(Andersen	et	al.,	
2001). The forward and reverse mutagenesis primers were designed using the DNA Star Lasergene software. 
The PCR reaction comprised of LIC primers and Phusion Flash High-Fidelity PCR Master Mix (Thermo Fisher 
Scientific) or Herculase II Fusion DNA Polymerase (Agilent). All PTPx-pOPIN sequences were evaluated by 
using BigDye® Terminator v3.1 Cycle Sequencing Kit (Thermo Scientific). The plasmids were extracted from 
transformed E.coli XL - 10 Gold ultracompetent cells using a high content NucleoBond® Xtra Midi EF 
(Macherey-Nagel) according to the manufacturer’s protocol. The site of mutation, sequences of the LIC and 
mutagenesis primers are listed in (Table 2.1). 
POLYMERASE CHAIN REACTION  
Mutation was introduced into the WT PTPX cDNA by an overlap extension PCR and was later cloned into 
their respective plasmid backbone by using LIC strategy. Herculase II fusion DNA polymerase was used along 
with dNTPs and 5x Herculase buffer obtained from the Herculase kit (Agilent Technologies). A calculated 
amount of DNA was added to the reaction mix with 10 µM of designed primers. To optimize the PCR reaction 
different DMSO concentrations were used. All volumes of the components for the reaction mix are listed in  
Component Volume 
5 x Herculase II reaction Buffer 10 µl 
25 mM dNTPs 1 µl 
Herculase II fusion DNA polymerase 1 µl 
Primer forward 1.25 µl 
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Primer reverse 1.25 µl 
50 ng plasmid DNA  0.33 µl 
DMSO 0 / 3 / 6 / 8 % 0 / 1.5 / 3 / 4 µl  
dd water X µl to final 50 µl volume 
 
The Mastercycler (Eppendorf) was used with a thermal cycle program as described in following	Table. A 2-
step PCR protocol was used wherein the first cycle governs association and amplification of the cDNA through 
its complimentary part of the LIC primers. The second cycle fuses the two PCR products. 
 Temperature Time Cycle 
Initialization 98 °C 1 min 1 X 
Denaturation 95 °C 20 sec 3 X 
Annealing 50.1 °C 20 sec 3 X 
Extension 72 °C 45 sec 3 X 
Denaturation 95 °C 20 sec 30 X 
Annealing 58.8 °C 20 sec 30 X 
Extension 72 °C 45 sec 30 X 
Final extension 72 °C 1 min 1 X 
Hold 8 °C   
 
SEPARATION AND PURIFICATION OF THE PCR PRODUCT 
PCR products were separated using electrophoresis in a 1.0 % agarose gel for 45 min at 120 V. Furthermore, 
RedSafe, a DNA binding dye was added at a concentration of 50µl/l to detect the PCR product. Also, 10 µl 
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2log ladder was loaded to the gel. The band with the expected size was cut out of the gel with help of the Safe 
imager (Invitrogen). The PCR product was purified by Zymoclean Gel DNA recovery kit and the concentration 
was measured with help of the Nanodrop at 260 nm.  
LIGATION 
To create 5’ overhang the PCR product and RE site cut pOPINE vector was incubated with the T4 DNA 
Polymerase. The components of the reaction mix are listed in the	following	table. 
Components Volume 
10 X NEB2 Buffer  2 µl 
T4 DNA Polymerase 0.2 µl 
100X BSA 0.2 µl 
Insert 9 µl 
dd water add to 20 µl 
 
The mixtures were incubated for 1 h at 22 °C and later the enzyme was heat inactivated at 75 °C for 20 min. 
The pOPINE vector was also incubated with this polymerase to create similar single-strand 5’ overhang. The 
concentration of T4 DNA polymerase treated PCR product and vector was determined. Two different ratios of 
vector to insert were used; 1:1 and 1:2. For calculating the quantity of the insert, the following equation was 
used: 
𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛	𝐼𝑛𝑠𝑒𝑟𝑡	𝐷𝑁𝐴	 𝑛𝑔 = 𝑉𝑒𝑐𝑡𝑜𝑟	𝑐𝑜𝑛𝑐. 𝑛𝑔 ∙ 𝐼𝑛𝑠𝑒𝑟𝑡	𝑠𝑖𝑧𝑒	[𝑏𝑝]𝑉𝑒𝑐𝑡𝑜𝑟	𝑠𝑖𝑧𝑒	[𝑏𝑝]  
The reaction mix was incubated for 30 min at 37 °C with 1X T4 DNA Ligase Buffer. 
After the annealing reaction, 5 µl of the reaction mix was used for transformation into chemical competent 
E. coli cells that complete the assembly by recombination.  
TRANSFORMATION  
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Aliquots of 45 µl XL10-Gold (Stratagen) or SCS-110 Stratagen) chemical-competent cells were thawed on ice 
and mixed with 2 µl β-Mercapto-ethanol (SERVA Electrophoresis GmbH). The mixture was incubated for 10 
min on ice. After incubation, 2 µl DpnI digested PCR product was added and cells were incubated for 30 min 
on ice. Cells were heat-shocked at 42°C for 30 s and placed back on ice for 2 min. 500 µl SOC medium was 
added cells were incubate for 1 h under moving at 37°C. Cells were shortly centrifuged down and most of the 
medium removed. Cells were resuspended in the remaining medium and plated on an agarose/LB plate 
containing Ampicillin. Plates were incubated over night at 37°C. On the next day, single colonies were selected 
and incubated in 5 ml LB containing 100 µg/ml Amp. Single clone cultures were incubated over night at 37 
°C under moving. 
ISOLATION AND PURIFICATION OF PLASMID DNA 
The aforementioned overnight culture was used for plasmid isolation using the Roti-Prep Plasmid Kit from 
Roth. All steps were performed as outlined in the manual. For elution of the plasmid DNA from the silica gel 
membrane, 30 µl of warm nuclease free water was used. Furthermore, these overnight cultures were needed 
for plasmid DNA purification. The overnight culture of the transfected XL10 Gold E. coli cells was transferred 
to a flask containing 250 ml TB media for growing a second overnight culture of the E. coli cells. The next day 
the optical density was measured at 600 nm for adjusting the cell mass and culture volumes for high-copy 
plasmids purification. All following purifications steps were performed with the Endotoxin-free plasmid DNA 
purification Kit (Macherey Nagel). For the reconstitution of the plasmids 200 µl nuclease free water was used, 
afterwards the concentration was determined with the Nanodrop. 
RESTRICTION CONTROL OF THE PLASMID 
For a first indication whether the insert and vector were ligated correctly, the plasmid DNA was cut into pieces 
using restriction enzymes, which cleaved the plasmid at specific palindromic sequences. The control vector 
exhibits a defined amount of restriction enzyme sites. The ligation of insert and vector can influence the amount 
of restriction enzyme sites so as to change the size of the cut plasmid sequences. For this control, the restriction 
enzyme BglI form NEB was used. The reaction mix was prepared and incubated for 2 h at 37 °C. For 
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inactivation of the enzyme an incubation time of 20 min at 65 °C was chosen. Afterwards, the cut plasmid 
sequences were separated in an agarose gel. 
Components Volume 
3.1 NEBuffer 5 µl 
Restiction BglI enzyme 1 µl 
Plasmid 1 µg 
dd water add to 50 µl 
 
SEQUENCING 
The BigDye Terminator v1.1 cycle sequencing Kit was utilized for performing fluorescence-based cycle 
sequencing reactions. This method is based on the Sanger sequencing also called dye-terminator sequencing 
that can be performed in one reaction. The buffers remaining from this kit contained all required components 
for the sequencing reaction. This buffer contains the polymerase and the dNTPs as well as four version of 
ddNTP-dye conjugates.  
Components Volume 
Premix BigDye 2 µl 
5x Buffer 3 µl 
Primer 0.5 µl 
DNA x µl 
dd water add to 20 µl 
 
In this type of PCR reaction the polymerase extends the DNA strand by addition of unmodified dNTPs. The 
reaction stops when the labeled dideoxynucleotide gets introduced into the strand. After the PCR, the products 
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are purified with the Nucelo colums Kit. The samples are then dried for 1 hour at 60 °C in a vacuum. With the 
help of electrophoresis procedure, the amplified strands with distinct length get separated. Afterwards the 
intensities of the labeled dideoxynucleotides for each position can be measured so that a chromatogram of the 
sequence could be established. 
Temperature Time Cycle 
96 ˚C 1 min  
96 ˚C 10 sec 25x 
50 ˚C 5 sec 25x 
60 ˚C 4 min 25x 
hold 4 ˚C   
 
2.2.2 CELL CULTURE 
MCF-7 cells (ECACC, Cat. No. 86012803) were cultured in Dulbecco’s modified Eagle’s medium (DMEM) 
(PAN Biotech), supplemented with 10% heat-inactivated fetal calf serum (FCS) (PAN Biotech), 10mM 
glutamine (PAN Biotech), 1% Non-Essential Amino Acids (PAN Biotech), 100U/ml penicillin (Gibco) and 
100U/ml streptomycin (Gibco) at 37ºC with 5% CO2. MCF7 cells were authenticated by Short Tandem Repeat 
(STR) analysis (Leibniz-Institut DSMZ). Cells were regularly tested for mycoplasma contamination using 
MycoAlert Mycoplasma detection kit (Lonza). 
2.2.3 MRNA PROFILING 
MCF7 cells were trypsinized and 6x105 cells were suspended in 4ml RNAse free water (Thermo Scientific) 
with 1ml RNA Later (Thermo Scientific). mRNA extraction and profiling was performed by Comprehensive 
Biomarker Center GmbH, Heidelberg on an array designed by Agilent 60-mer Sure print technology. The 
mRNA levels were obtained from three independent runs. 
2.2.4 TRANSFECTION 
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3x104 MCF7 cells were seeded per well in an 8-well Lab-Tek chamber (Nunc). After 7-8 h of seeding, cells 
were transfected with 0.125µg of each plasmid (EGFR-mTFP, PTPX-mCitrine or cCBL-BFP) by using 
FUGENE6 (Roche Diagnostics). The cells were incubated along with the transfection mixture overnight at 
37°C with 5% CO2. Before EGF stimulation, cells were growth factor starved with supplemented DMEM (see 
above) without FCS for 6h. The cells were stimulated with a sustained or a 5min-pulse of 200ng/ml EGF-
Alexa647. Cells were chemically fixed with Roti® Histofix 4% (Carl Roth) for 20 min, washed three times 
with PBS and then permeabilized with 0.1% Triton-X/PBS (SERVA Electrophoresis) for 15min. Cells were 
stored with PBS at 4°C before immunostaining. For the siRNA mediated knockdown experiments, 2×104 of 
MCF7 cells were seeded in each well of an 8-well Labtek dish and were transfected after 24h using 50nM 
siRNA specific for PTPN2, PTPRG, PTPRJ or non-targeting control siRNA with Dharmafect1 according to 
the manufacturer’s instructions. 
2.2.5 SIRNA CONCENTRATION OPTIMIZATION FOR THE KNOCK-
DOWN EXPERIMENTS 
2×105 of MCF7 cells were seeded in each well of a 6-well tissue culture dish and transfected after 24h using 
50nM siRNA specific for PTPN2, PTPRG, PTPRJ, or non-targeting control siRNA with Dharmafect1 
according to the manufacturer’s instructions. RNA was isolated 24h after transfection using the Quick-RNA 
MicroPrep kit (Zymo Research, Freiburg, Germany). For quantification of the mRNA expression levels of 
interest, 1µg of the isolated RNA was used for reverse transcription using the High Capacity Reverse 
Transcription kit (Applied Biosystems) according to the manufacturer instructions. Commercially available 
TaqMan assays (Thermo Fisher), PTPN2(Hs00959888_g1), PTPRG(Hs00892788_m1), 
PTPRJ(Hs01119326_m1), GAPDH(Hs02786624_g1), CYBA(Hs00609145_m1) were used to detect the 
amplicons after each cycle of a qPCR reaction ran in an IQ5 real-time PCR system cycler (Bio-Rad). Cycling 
condition were as follows: 40 cycles of 95°C for 10s and 57°C for 30s. Data were analyzed using the ΔΔCt 
method for determination of relative gene expression by normalization to an internal control gene (GAPDH), 
and fold expression change was determined compared to the control siRNA sample.  
2.2.6 PROTEIN AND PEPTIDE CONJUGATION REACTION 
HEGF-ALEXA647 
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His-CBD-Intein-(Cys)-hEGF-(Cys) plasmid (Sonntag	 et	 al.,	 2014) was kindly provided by Prof. Luc 
Brunsveld, University of Technology, Eindhoven. Human EGF was purified from E. coli BL21 (DE3) and was 
labelled at its N terminus with Alexa647-maleimide as previously described(Sonntag et al., 2014). Labelled 
EGF-Alexa647 was stored in PBS at -20°C. 
PY72-CY3.5 LABELLING 
Cy3.5® NHS ester (GE Healthcare) was dissolved in 10µl of dried N,N dimethylformamide (SERVA 
Electrophoresis). For each reaction, 15µl of 1 M Bicine (pH 9.0) and 10-fold molar excess (to PY72) of Cy3.5 
was added to 100µl PY72 (0.25mg/ml) in PBS. The reaction was allowed for 20min in the dark and was 
terminated by adding 6µl of 0.2M Tris buffer (pH 6.8). Free dye was removed by using 7K Zeba Spin Desalting 
Columns (Thermo Scientific). The absorption (A) of the filtrate was measured at 280nm (PY72) and 581nm 
(Cy3.5). For immunostaining, labelled antibody (30µg/ml in PBS) with dye to protein ratio of 3 - 5 was used. 
( CDEFGHIEJK = LMNO∗O.QLRNSTS.RU∗LMNO ∗O.M)  
2.2.7 HIGH-CONTENT SCREENING 
After 12-14 hours of transfection, cells were starved for 6 hours (DMEM 0 % FCS) and stimulated with 200 
ng/ml EGF for indicated times according to the experiment. The stimulus was removed after the first 5 min 
and replaced by starving medium. Cells were chemically fixed with 4 % PFA/PBS (Sigma-Aldrich) for 20min. 
Cells were washed 3x with TBS and 10 min permeabilized with 0.1 % Triton-X/PBS (SERVA Electrophoresis 
GmbH). Afterwards, cells were stained for 10 min with 0.5 ng/ml Hoechst (Molecular Probes). The 8-well dish 
were placed on a metal stage holder and fixed with superglue. After calibrating the system, every center 
position of each well was focused and saved (2 positions per well). A grid of 5x5 subpositions was chosen that 
used the saved position as a center and acquired 25 images around it. At every subposition, the sample plane 
was auto-focused in the Hoechst channel. Fluorescent images and FLIM-stacks were acquired at each 
subposition before and after addition of the FRET acceptor (anti-pY-Cy3.5).  
2.2.8 TRAPPING MUTANT FLIM 
Confocal FLIM experiments were performed using a time-correlated single-photon counting module (LSM 
Upgrade Kit, PicoQuant) on an Olympus FV1000 confocal microscope (see: Confocal microscopy). Pulsed 
lasers were controlled with the Sepia II software (PicoQuant) at a pulse repetition frequency of 40MHz. The 
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sample was excited using a 440nm diode laser (LDH 440, PicoQuant). Fluorescence emission was spectrally 
filtered using a narrow-band emission filter (HQ 480/20, Chroma). Photons were detected using a single-
photon counting avalanche photodiode (PDM Series, MPD, PicoQuant) and timed using a single-photon 
counting module (PicoHarp 300, PicoQuant). Using the SymPhoTime software V5.13 (PicoQuant), images 
were collected after an integration time of ~ 4min collecting ~ 3.0–5.0x106 photons. For each pixel, the single 
photon arrival times of the TCSPC measurement were used to calculate the complex Fourier coefficients of 
the first harmonic and were corrected by the Fourier coefficient of a calculated reference (Grecco et al., 2010).  
2.2.9 IMMUNOFLUORESCENCE IMAGING 
Permeabilized cells were incubated with 200µl of Odyssey Blocking buffer (LI-COR) for 30min. All the 
antibodies were diluted in Odyssey Blocking buffer (LI-COR). Primary antibodies were applied for 1h and 
fluorescently tagged (Alexa568) secondary antibodies for 30min. Cells were washed three times with PBS 
between each antibody incubation step. Cells were imaged in PBS at 37°C. The Olympus FluoView FV1000 
confocal microscope was equipped with a temperature-controlled CO2 incubation chamber at 37˚C and a 
60x/1.35 NA Oil UPLSApo objective (Olympus Life Science). Fluorescent fusion proteins with BFP, mTFP 
and mCitrine were excited using the 405nm Diode-UV laser (FV5-LD05, Hatagaya) and the 458/488nm lines 
of an Argon-laser (GLG 3135, Showa Optronics). Cy3.5/Alexa568 were excited with a 561nm DPSS laser (85-
YCA-020-230, Melles Griot) and Alexa647 was excited with a 633nm He-Ne laser (05LHP-991, Melles Griot). 
Detection of fluorescence emission was restricted with an Acousto-Optical Beam Splitter (AOBS): BFP (425-
450nm), mTFP (472-502nm), mCitrine (525-555nm), Cy3.5/Alexa568 (572-600nm), Alexa647 (655-755nm). 
Scanning was performed in frame-by-frame sequential mode with 3x frame averaging and a pinhole of 2.5 airy 
units.  
2.2.10 QUANTIFICATION AND STATISTICAL ANALYSIS 
GLOBAL ANALYSIS OF FLIM DATA 
The global analysis of FLIM data uses the whole image (=global) set to extrapolate the decay 
rate of the donor molecules without (D) and with an acceptor molecule (DA). That then uses 
the information in each pixel of an image to determine the fraction of donor molecules 
(EGFR-FP) interacting with an acceptor molecule. 
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If we have two different lifetimes from donor only molecules and donor molecules 
interacting with acceptor molecules in a certain configuration, the fraction (a) of interacting 
molecules within each pixel can be calculated according to: 
𝛼 𝑥, 𝑦 = 	 𝜏CL𝐴CL(𝑥, 𝑦)𝜏C𝐴C 𝑥, 𝑦 + 𝜏CL𝐴CL(𝑥, 𝑦) 
where AD is the amplitude of the donor only molecules and ADA the amplitude of the 
acceptor-bound donor molecules and tD and tDA are the corresponding lifetimes. 
For global analysis, the single photon arrival times of the TCSPC measurement for each 
pixel were used to calculate the complex Fourier coefficients of the first harmonic (Grecco 
et al., 2009). In a second step the Fourier coefficients were corrected by the Fourier 
coefficient of a calculated reference. The corrected Fourier coefficients are then plotted into 
a phasor plot, so that the Fourier coefficients from each pixel of the image set are represented 
by one point in the phasor plot (Figure 2-2-1).  
Figure 2-2-1 Phasor plot showing a linear fit of the fluorescence emission Fourier 
coefficients (R) in the complex plane yielding the global lifetimes in presence (τDA) and 
absence (τD) of FRET. Fraction of donor molecules interacting with the acceptor (α) in each 
pixel was calculated from the projection onto the τD-τDA line segment. An exemplary 
spatially resolved α-map (right) are shown. Scale bar: 20µm.  
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By fitting a straight line through all points in the phasor plot, the “global lifetimes” τD and 
τDA are determined at the intersections with the half-circle. τDA is the donor fluorescence 
lifetime in presence of the acceptor and τD the donor-only lifetime. Finally, the projection of 
each point in the phasor plot into the fitted segment between τD and τDA can be used to 
calculate the relative fraction of donor-only and donor-acceptor pairs (α) in each pixel. 
SINGLE CELL SEGMENTATION AND QUANTIFICATION 
Cells were segmented in CellProfiler (Kamentsky et al., 2011) using the image of the nuclear stain (Hoechst) 
and EGFR-mTFP. All images were corrected for background and bleed through, and mean values per cell 
(excluding the nuclear region) from all channels were obtained. To match the images of the FLIM MCP and 
the high-resolution CCD camera, the masks were affine transformed (OpenCV). 
PTP SPECIFIC REACTIVITY 
The αmedian of each cell was plotted against the respective PTPX–mCitrine mean intensity per cell for each time 
point. If the distributions of αmedian, PTPx and αmedian, ctr were significantly different (Mann–Whitney U, p<0.05), 
the data was fitted with an exponential function (𝛼 = 𝑐 + 𝐴 ∙ 𝑒T^∙F_F`). For each time point, the cells of the 
respective control measurement were included in the fit after removing outliers (± 3x median absolute deviation 
around the median). The control coefficient that reflects the dephosphorylating efficiency of each PTPX was 
determined from the slope of the exponential function at 0 calculated from –k*A, where k is the rate and A is 
the amplitude. For weak α - PTPX-mCitrine intensity dependencies, the control coefficients were determined 
from the slope of a linear fit. 
SPATIAL-TEMPORAL MAPS (STMS) 
Cells were masked from the EGFR images using FIJI (https://fiji.sc/), the nuclei were segmented using 
CellProfiler from the nuclear stain (Hoechst) or cCBL-BFP images. The distribution of observables or derived 
quantities in cell was determined by obtaining radial profile upon single cell analysis by using Python based 
Segmentor tool developed by Dr Klaus Schuermann. 
For each pixel within the cell, the distance to the closest PM and nuclear membrane (NM) were calculated to 
derive a normalized distance r = rPM / (rPM + rNM). All pixels were split in 10 intervals according to their 
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normalized distances. For each of the observables (EGFR-mTFP, PTPX-mCitrine, pYi-Alexa568, and EGF-
Alexa647 fluorescence intensities) or derived quantities (α, pYi-Alexa568/ EGFR-mTFP, EGF-Alexa647/ 
EGFR-mTFP, PFC), the mean value was calculated for each segment, yielding a radial profile for the individual 
cells. To calculate the radial distribution of EGFR-mTFP phosphorylation at distinct pYi sites, the mean 
fluorescence per segment of the pYi channel was divided by the corresponding mean EGFR-mTFP 
fluorescence. With the exception of α and pYi/EGFR-mTFP images, all profiles were divided by the total cell 
mean and an average radial profile was calculated. The radial profiles from the distinct time points were then 
combined to yield the corresponding spatial-temporal maps. Cells in which PTPX-mCitrine expression levels 
saturated EGFR dephosphorylation were excluded from the analysis (Fig. S4b, explanation below). 
The STM of the phosphorylation fold-change (PFC) was calculated by dividing the STM pYi /EGFR-mTFP of 
the control by the STM pYi/EGFR-mTFP for each PTPX-mCitrine. The profiles from multiple experiments 
were averaged and significance was determined using 𝑘 (T bc ^ )dJ!KTOJfS ,  where 𝑘 = 𝑝JK , and pi denotes the 
individual p-values from a Student’s t-test comparing the pYi /EGFR-mTFP distributions of the control to that 
upon the respective PTPX-mCitrine expression at each point in space and time.  
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 RESULTS 
 
3.1 DETERMINING EGFR-PTP INTERACTION 
In order to evaluate if the PTPs identified in the reciprocal perturbation screening are direct 
negative regulators of EGFR, PTP-mCitrine trapping mutants (TM) were generated by 
modifying the catalytic site Cysteine to Serine (C/S), Aspartate to Alanine (D/A) or C/S with 
D/A (Double mutants-DM)(Blanchetot et al., 2005; Flint et al., 1997). To assess the 
interaction between PTPx-mCitrine and EGFR-mTFP, we used a FRET-FLIM approach 
where mTFP that is tagged to EGFR acts as a donor and mCitrine tagged to PTPx acts as an 
acceptor. The MCF7 cells ectopically expressing PTPXTM-mCitrine and EGFR-mTFP were 
stimulated with 5 min pulse (5P) of 200ng EGF, which allowed identifying PTPs that interact 
with ligandless EGFR and liganded EGFR. 
Figure 3-1 Average fraction of EGFR-mTFP interacting with catalytically impaired PTPX-mCitrine trapping 
mutants (αTM ± SD, n=15-20 cells, * p<0.05, ** p<0.01 and *** p<0.001). MCF7 cells ectopically expressing 
PTPxTM –mCitrine and EGFR-mTFP were stimulated with 5P-200ng EGF for 30min and 120 min time point. 
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Out of various trapping mutant versions of each of the PTPs, i.e C/S, D/A and DM, only 
those mutants that showed strongest interaction are represented (Figure 3-1). PTPN1/2/9 and 
PTPRA/E/G strongly interact with unstimulated EGFR implying that these PTPs have a 
potential to act on the ligandless autonomously activated EGFR and play an important role 
in its safeguard mechanism (Baumdick et al., 2015). The interaction of ER-PTPs is stronger 
as compared to the R-PTPs, due to various factors. First, there is a structural difference in 
the catalyitc site of ER-PTPs, cyt-PTPs and R-PTPs. Unlike ER-PTP, binding of cyt-PTPs 
and R-PTP to its substrate is determined by both their catalytic sites and other domains that 
affect the efficiency of these PTPs towards their similar substrate (Sarmiento et al., 2000). 
Upon stimulation, all PTPs except PTPRG showed an increase in interaction with liganded 
EGFR. PTPRA on the other hand showed an increase in interaction only at late time points 
which indicates some kind of regulation that inhibits its binding to the substrate at early time 
points. The interaction also depends on the spatial localization of the PTPs which determines 
the substrate accessibility. The increase in interaction of EGFR to ER- bound PTPN1/N2 
can be only availed by vesicular trafficking as it is a primary mode through which an 
interaction between ER localized-PTP and plasma membrane localized EGFR can be 
accomplished, making it an important part of the EGFR phosphorylation-dephosphorylation 
cycle (Baumdick et al., 2015). 
3.2 REGULATION OF THE TEMPORAL EGFR PHOSPHORYLATION 
PROFILE BY PTPS 
The reciprocal perturbations (Figure 1-7) singled out the non-redundant PTPs and implied 
the direct regulators of EGFR on the basis of siRNA and cDNA perturbation, respectively. 
While the interaction studies showed which and when these PTPs interact with EGFR, the  
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Figure 3- 2 A) Competition based epitope mapping of generic anti-phosphotyrosine pY72. (± SD, n=100-
120 cells, **** p<0.0001). B) Temporal phosphorylation EGFR profile obtained upon ectopic EGFR-
mTFP expression and 5P-200ng EGFR stimulation using pY72 and anti-EGFR pY1068 antibody on 
western blots 
Figure 3- 3 Exemplary temporal EGFR-mTFP 
phosphorylation profiles (grey, control; blue; co-
PTPN2-mCitrine expression) The violin plots show 
the α distributions from single cells stimulated with 
200ng/ml 5P-EGF (number of cells denoted on top 
of the plots, medians at different time points are 
connected). 
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reactivity of an enzyme is not always a reflection of its interaction with its substrate. To 
determine regulation of the temporal response of pEGFR to 5P-EGF stimulation by PTPs, 
high-content imaging experiments were performed. MCF7 cells ectopically expressing 
EGFR-mTFP and PTPx-mCitrine were stimulated for 0, 5, 30 and 120 min with 200ng 5P-
EGF and were chemically fixed. EGFR has 6-7 signaling tyrosine residues and the 
phosphorylation dynamics of these individual residues are not clear. Therefore, we used a 
generic anti-phosphotyrosine antibody (PY72) (Grecco et al., 2010)to identify most of the 
phosphorylated tyrosine residue on EGFR. Epitope mapping experiments showed that PY72 
predominantly binds to pY1045 and pY1173 sites of EGFR (Figure 3-2).  As this antibody 
can potentially identify phosphorylated tyrosine on every protein in a cell, a FRET-FLIM 
approach was used to calculate the fraction of EGFR that interacts with PY72-CY3.5. The 
fluorescent protein mTFP at the C-terminal of EGFR acts as a FRET donor to Cy3.5 dye 
conjugated to PY72. To confirm that the temporal profile obtained by PY72 reflects EGFR 
signaling, lysates of MCF7 cells ectopically expressing EGFR-mTFP and stimulated with 
5P-200ng were blotted and stained with PY72 and an anti-pY1068 antibody which 
represents a Grb2 mediated signaling tyrosine residue. The sustained EGFR phosphorylation 
temporal profile for both PY72 and pY1068 demonstrated that PY72 follows the EGFR 
signaling response. Using a in-house built automated microscopy set-up we were able to 
acquire 50 fields of views with 7-12 cells per field. This provided us with enough cells to 
exploit the cell to cell variance in PTP expression and determine enzymatic strength of each 
PTP over time on EGFR phosphorylation.  
The temporal EGFR phosphorylation profile represented as 𝑃𝐹𝐶j (wheren in, 𝑃𝐹𝐶j =	𝛼kHKIGHl	/𝛼F_F` ) with ectopic PTPx-mCitrine expression shows that ER-localized PTPN2 
and predominantly plasma membrane localized PTPRE/RF/RG/RJ strongly 
dephosphorylate ligand activated EGFR as compared to the other PTPs (Figure 3-3). 
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Although these 𝑃𝐹𝐶j profiles provided a general view of a cellular population in regulating 
phosphorylation-dephosphorylation of EGFR in presence of a particular PTP, it does not 
account for the variance in PTPx-mCitrine expression in each cell that can affect EGFR 
differently (Figure 3-4). Generally, to our observation Receptor-PTPs are expressed weakly 
as compared to the cytosolic or ER-bound PTPs. A catalytically weak phosphatase will be 
required in high concentration as compared to a potent phosphatase in dephosphorylating 
EGFR with similar magnitude. 
As we obtained nearly 50-100 cells for each PTPX per stimulation time-point, it was possible 
to determine an impact of varied PTPX –mCitrine expression on pEGFR by correlating the 
alpha to PTPx-mCitrine expression in each cell. The p values obtained by spearman 
Figure 3- 4 Interleaved temporal bar plots of median EGFR phosphorylation fold-changes( αkIG αF_F+  
±MAD n~150 cells per condition) upon ectopic PTPX-mCitrine expression stimulated 5P-200ng EGFR for 
30 min and 120 min time-point. 
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correlation ranking (Figure 3-5) showed that at all time point for PTPRF, there is no 
correlation between alpha and PTPx-mCitrine expression. Implying there might be another 
parameter that can play a role in regulating PTPRF effect on EGFR. 
To determine the strength of each PTPs, median alpha of the control was anchored on to the 
Y-axis from which an exponential/linear fit to the scatter plot was drawn. The slopes (linear 
fit) or initial slopes (exponential fit) of α vs. PTPX-mCitrine fluorescence intensity were 
calculated for each EGF stimulation time point (Figure 3-5). This showed that the ER  
Figure 3- 5 α vs. PTPX-mCitrine 
single cell fluorescence scatter 
plots. Black circle: mean αctr±SD; 
black lines: exponential fits (* - 
linear fit for weak dependence, 
green asterisk: distributions of αctr 
and αPTP did not significantly 
differ); blue lines with error 
bounds: moving averages with 
standard deviations.  
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Figure 3- 7  Relative specific PTPX-mCitrine activities for 0, 5, 30 and 120min after 200ng/ml 5P-
EGF of stimulation with respective subcellular localization of PTPX-mCitrine. 
Figure 3- 6 PTPX and EGFR mRNA levels in MCF7 cells obtained from micro arrays (relative to 
GAPDH mRNA). AS: anti-sense. 
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localized PTPN2 and the PM localized PTPRG/RJ are the strongest regulators of EGFR 
phosphorylation. PTPRA and DUSP3, on the other hand, turned out to act weakly on the 
phosphorylated EGFR. As opposed to 𝑃𝐹𝐶j , the PTPx specific activity revealed PTPRE to 
be a weak phosphatase compared to that of PTPRJ (Figure 3-6). The mRNA expression 
profiling of MCF7 cells showed that PTPRG is expressed weakly in these cells as compared 
to the cytosolic/ER-PTPs (Figure 3-7). This, in conjunction with the effect seen upon siRNA 
silencing, corroborates its high activity. Interestingly, the mRNA profiling results also 
showed that MCF7 cells have a very low expression of EGFR, validating our approach of 
ectopic expression of EGFR to understand the role of PTPs on EGFR phosphorylation.  
The strong phosphatase activity of PTPN2 prior to EGF stimulation, implies its role in 
regulating autonomously activated EGFR hence validating its role in the safeguard 
mechanism. The strong regulation of pEGFR upon stimulation by juxtaposed subcellular 
localized ER-PTPN2 and PM-RG/RJ indicates they might play a specific role in regulating 
cell response upon ligand stimulation. As PY72 detects certain tyrosine residues of EGFR 
more efficiently, other phosphatases might play a role in regulating specific EGFR tyrosine 
sites, for e.g. pY845 which is important for autocatalysis (Baumdick et al., 2015; Sato, 2013).  
3.3 VESICULAR COMPONENTS PLAY AN IMPORTANT ROLE IN 
EGFR TRAFFICKING 
Vesicular trafficking is an essential machinery that brings RTK to phosphatase activity rich 
perinuclear region (Baumdick et al., 2015; Sabet et al., 2015). Upon binding to its ligand at 
the plasma membrane, EGFR gets internalized through a clathrin dependent/independent 
mechanism (Mayor et al., 2017) (See:Section 1.3). Ligand mediated EGFR activation leads 
to phosphorylation of Y1045 that acts as a binding site to cCbl, a ubiquitin ligase which adds 
ubiquitin to the lysine residues at the EGFR kinase domain(Grovdal et al., 2004). To 
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determine how cCbl influences 5P-EGF stimulated EGFR internalization, MCF7 cells 
ectopically expressing both EGFR-mTFP and cCbl-BFP or only EGFR-mTFP were 
stimulated with 200ng of 5P-EGF. The distribution of EGFR in the cell was determined by 
obtaining a radial profile for each individual cell Each cell was masked by using the EGFR-
mTFP intensity images and the nuclei were obtained from cCBL-BFP intensity images by 
using CellProfiler. For each pixel within the cell, the distance to the closest plasma 
membrane (PM) and nuclear membrane (NM) were calculated to derive a normalized 
distance r = rPM / (rPM + rNM) (Figure 3-8). All pixels were split in 10 intervals according to 
their normalized distances. The mean value was calculated for each segment for each 
observable, yielding a radial profile for the individual cells (Figure 3-8). 
Figure 3- 8 A) Dimensionality reduction from Cartesian (x, y) to normalized radial (r) distribution of 
quantity (Q) between the plasma (PM) and the nuclear (NM) membrane. B) Averaged radial profile of 
EGFR-mTFP fluorescence obtained from MCF7 cells ectopically expressing EGFR-mTFP along with or 
without co-ectopic expression of cCbl-BFP. Cells were stimulated with 200ng/ml 5P-EGF and chemically 
fixed. n=~30 cells 
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The averaged radial profile for ~30 cells showed that EGFR is internalized and is distributed 
to the perinuclear region with time in presence of cCbl-BFP (Figure 3-8). The internalization 
however occurs through small vesicles that fuse to RAB5 positive early endosomes (Bucci 
et al., 1992). These early endosomes then mature into Rab7 positive late endosomes through 
which EGFR is directed to lysosomes for degradation (Vanlandingham and Ceresa, 2009). 
The immunostaining for RAB5 and RAB7 shows that upon EGF stimulation, EGFR 
colocalizes with RAB5 positive endosomes near the plasma membrane and is distributed in 
the cell. At late time points, EGFR colocalizes with the perinuclear RAB7 positive 
compartment suggesting molecules that are subjected to degradation. A small fraction of 
EGFR in the RAB5 positive early endosomes at 120min (Figure 3-9) shows a consistent 
activity of the vesicular trafficking machinery in distributing activated EGFR. The signaling 
EGFR molecules that escape this unidirectional trafficking, i.e. not subjected to lysosomal 
degradation are deactivated by a complimentary mechanism, that is, via dephosphorylation 
by PTPs. 
Figure 3- 9 A) Exemplary merged (third row) and individual image sets of EGFR-mTFP and anti-RAB5-
Alexa568 fluorescence for 0,5,30 and 120min after 200ng/ml 5P-EGF stimulated and chemically fixed MCF7 
cells. B) Similar set of images are represented for RAB7. 
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3.4 HOW PTPS MODULATE EGFR RECYCLING? 
A complete shutdown of EGFR signaling requires its trafficking to perinuclear area where 
it interacts with ER-PTPs. Considering phosphorylation of EGFR Y1045 site serves as a 
docking site for cCbl that ubiquitinates EGFR availing an efficient internalization, regulation 
of this site by PTPs affect its trafficking to lysosomes; instead they allow recycling of EGFR 
back to the plasma membrane (Baumdick et al., 2015; Grovdal et al., 2004; Ravid et al., 
2004). To examine how strong negative regulator PTPN2, PTPRG and PTPRJ affect pEGFR 
Y1045, MCF7 cells ectopically expressing EGFR-mTFP, cCbl-BFP and PTPx-Citrine were 
stimulated with 5P-200 ng EGF and were chemically fixed before staining it with EGFR-
pY1045 following immunostaining protocol.  
As represented in Figure 3-10, in the control condition i.e. cells expressing EGFR-mTFP 
and cCbl-BFP, massive phosphorylation of EGFR at the plasma membrane at early time-
point indicates ligand stimulation is necessary for an efficient phosphorylation of pY1045. 
Interestingly, at 120 min most of the EGFR molecules were dephosphorylated in the 
Figure 3- 10 A) Exemplary image sets of EGFR-mTFP, EGF-Alexa647, anti-pY1045-Alexa568 fluorescence 
and phosphorylated pY1045 fraction (pY1045/EGFR-mTFP) at 0,5,30 and 120min after 200ng/ml 5P-EGF 
stimulation of MCF7 cells Scale bar: 50µm. B) Phosphorylation fold change 𝑃𝐹𝐶OSUMupon ectopic expression 
of PTPN2, PTPRG or PTPRJ; n~30-40 cells 
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perinuclear region, which entails that the endogenous ER-PTPs like PTPN1 and PTPN2 are 
capable of acting efficiently on ectopically expressed EGFR-mTFP. However, the 
phosphorylated fraction of EGFR molecules at the plasma membrane at late time points 
implies autocatalytic activity of the monomeric EGFR molecules that are recycled back to 
the plasma membrane and that act on other ligandless EGFR molecules. To evaluate how 
phosphorylation of EGFR Y1045 is affected upon PTPX expression, 𝑃𝐹𝐶opOSUM (𝑐𝐷𝑁𝐴 −𝑃𝐹𝐶opOSUM/F_F` = (opOSUM/rstu)vwx(opOSUM/rstu)yzy{) for each time point was determined. This showed that 
PTPN2, PTPRG and PTPRJ significantly affected phosphorylation of pY1045. Among the 
three PTPs, PTPN2 and PTPRG had a stronger effect on pY1045 phosphorylation before 
stimulation indicating its role in inhibiting internalization or promoting recycling of 
spontaneously activated EGFR molecules. The increase in activity over EGFR by PTPN2 
and PTPRJ show their role in acting on liganded receptors. PTPRG on the other hand showed 
a sustained activity indicating it has no or very less impact of ligand bound EGFR molecules.  
3.5 SPATIAL DISTRIBUTION OF PTPRG, PTPN2 AND PTPRJ 
DETERMINES ITS INTERACTION WITH EGFR 
 61 
 To assess how PTPX distribution is affected upon EGF stimulation, calculated radial profiles 
for each timepoint (Figure 3-8) and reconstructed 3D spatial-temporal maps (STM) to 
represent distribution of EGFR-mTFP, liganded EGFR (EGF-Alexa647/EGFR-mTFP) and 
PTPx-mCitrine in space and time. We also generated STMs for the 𝛼_| for PTPN2 and 
PTPRG/J to understand how the PTP distribution correlates with their interaction with 
EGFR.  
Figure 3- 11 STMs depicting A) EGFR-mTFP fluorescence and B) calculated fraction 
of EGFR bound to EGD (EGF-EGFR) C) PTPX-mCitrine fluroscence (top) and 
fraction of EGFR-mTFP interacting with PTPXTM-mCitrine (bottom) (TM-PTPN2 
(C216S); PTPRG (C1060S); PTPRJ (D1205A)) 
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The STM of EGFR-mTFP shows that the EGFR present on the plasma membrane is 
distributed to the perinuclear region at late time point which constitutes mostly EGFR 
molecules that are bound to EGF (STM of EGF-EGFR). The PTPx-STMs showed that 
PTPN2-mCitrine is predominantly localized in the perinuclear area but is also present in 
lower amount near the cell. This explains its ability to interact with EGFR at early-time 
points (Figure 3-11) and to strongly dephosphorylate pY1045 (Figure 3-10) and hence plays 
a major role in maintaining ligandless EGFR on the plasma membrane. The increased 
interaction with EGFR at later time-points hints that PTPN2 acts on liganded receptors and 
can regulate the temporal phosphorylation profile. PTPRG/RJ-mCitrine, on the other hand 
showed higher concentrations at the plasma membrane, which further increased upon EGF 
stimulation. The increase in translocation upon EGF stimulation suggests PTPRG/RJ 
employs the EGFR vesicular trafficking machinery. Unlike PTPRJ that showed an increase 
in interaction with liganded EGFR, PTPRG-mCitrine interacted with monomeric EGFR 
(unstimulated) and did not show any increase in interaction upon stimulation. This indicates 
that PTPRG directly interacts with the recycling ligandless EGFR and hence possibly plays 
an important role in determining EGFR-EGF response properties. By interacting with 
liganded EGFR, PTPRJ regulates the temporal profile of EGFR phosphorylation similar to 
PTPN2 but due to its presence on the plasma membrane, at later time points it is able to 
dephosphorylate any spontaneously activated EGFR. 
3.5 SPATIAL TEMPORAL MAPS FOR EGFRPY1068 REVEALS LOCAL 
PTP ACTIVITY 
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pY1068 is a Grb2 binding site through which the EGFR signal is propagated to the 
downstream proteins. To learn how spatially distributed PTPs coupled with differential 
vesicular dynamic system regulate EGFR signaling, we observed changes in 
phosphorylation of Y1068 in space and time.  
Figure 3- 12 Exemplary image sets of EGFR-mTFP, EGF-Alexa647, anti-pY1068-Alexa568 
fluorescence and phosphorylated pY1068 fraction (pY1068/EGFR-mTFP) at 0,5,30 and 120min after 
200ng/ml 5P-EGF stimulation of MCF7 cells Scale bar: 50µm. B) Immunofluorescence based 
antibody specificity test C) STMs depicting phosphorylation response on pY1068 signaling site 
(n~90, N=4).  
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The specificity of pY1068 was determined by immunofluorescence experiment using MCF7 
cell expressing wild type EGFR-mCitrine or EGFR-Y1068F-mCitrine. The reduced staining 
in case of EGFR-Y1068F-mCitrine proves that the antibody is specific to pY1068 site of 
EGFR (Figure 3-12 B). Spatial EGFR phosphorylation profile i.e. STMpY1068-norm 
(ratiometric immuno-pY1068-Alexa 568/EGFR-mTFP fluorescence) shows that the pY1068 
phosphorylation increased at the plasma membrane upon stimulation (Figure 3-12 A and C), 
while at 30 mins the signal mainly came from the internalized liganded EGFR molecules 
present in endosomes. To generate these STM maps only cells falling in the lower 15-35% 
of mTFP intensity range were chosen to avoid any artifact caused due to the ectopic 
expression of EGFR-mTFP. Therefore, an increase in phosphorylation of EGFR molecules 
at the plasma membrane can be accredited to the autocatalytic activity of the recycled 
ligandless EGFR. 
Figure 3- 13 Left: pY1068/EGFR vs. PTPN2-mCitrine fluorescence scatter plots were used to determine 
the PTPN2-mCitrine fluorescence intensity threshold at which saturation of EGFR dephosphorylation 
occurs. Blue/red circles: single cells with low/high PTPN2-mCitrine intensity with respect to saturation 
threshold (below/above); solid lines and shaded bounds: corresponding moving averages and standard 
deviation. 
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To determine the local specific activity of the ER-PTPN2 and receptor PTPRG/RJ over 
EGFR Y1068 phosphorylation, we derived the ratiometric maps of phosphorylation fold-
change ( 𝑐𝐷𝑁𝐴 − 𝑃𝐹𝐶opOS}N/F_F` = (opOS}N/rstu)vwx(opOS}N/rstu)yzy{ ) upon ectopic PTPX-mCitrine 
expression and (𝑠𝑖𝑅𝑁𝐴 − 𝑃𝐹𝐶opOS}N/F_F` = (opOS}N/rstu)vwx(opOS}N/rstu)yzy{)  upon siRNA mediated 
PTPx silencing. In order to also avoid overexpression artifacts on EGFR dephosphorylation, 
we analyzed cells with PTPX-mCitrine expression levels where EGFR phosphorylation was 
sensitive to the perturbation and disregarded cells with high or saturated concentration of 
PTPx as exhibited by the mCitrine intensity (Figure 3-13). Receptor-PTPs are weakly 
expressed as compared to the ER or cytosolic PTPs. Therefore, the 𝑐𝐷𝑁𝐴 −𝑃𝐹𝐶opOS}N/F_FR  were scaled by the corresponding average of the PTPx-mCitrine intensity. 
This scaling factor allowed us to compare the activity of differently expressed PTPs over 
EGFR.  
Figure 3- 14 STMs showing effect of A) PTPX-mCitrine expression (top-row) on 
phosphorylation fold-change (PFC-cDNA) reflecting the relative PTPX-mCitrine reactivity 
towards pY1068 upon 5P-EGF (n~60, N=3). B) Corresponding PFC-siRNA is shown in the 
second row (n~30, N=3). 
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Both 𝑐𝐷𝑁𝐴 − 𝑃𝐹𝐶opOS}N/F_F`  and 	𝑠𝑖𝑅𝑁𝐴 − 𝑃𝐹𝐶opOS}N/F_F`  (Figure 3-14) showed that 
PTPN2 dephosphorylated ligand activated EGFR. The dephosphorylation was confined 
mainly to the perinuclear region in case of ectopic expression of PTPN2-mCitrine upon 5P-
EGF stimulation. siRNA mediated knockdown of PTPN2 showed an effect on EGFR 
phosphorylation extended to the periphery of a cell. This reciprocal perturbation experiment 
proves that the ER-PTP like PTPN2 is crucial in determining signal duration. Not only it had 
an effect on liganded EGFR, but by acting on unstimulated EGFR it showed that PTPN2 
plays an important role in shutting down the autocatalytic activity of an autonomously 
activated ligandless EGFR molecule. 
Although local phosphatase activity of PTPRG/RJ is limited to the plasma membrane 
(Figure 3-14), their ability to act differently on liganded and ligandless EGFR associate them 
to a specific role in regulating EGFR response. PTPRG strongly dephosphorylated EGFR 
before stimulation. However, its activity was affected upon GF stimulation at early timepoint 
implying an underlying biochemical regulation like GF triggered ROS mediated inhibition 
of its activity. At later time points, an increase in dephosphorylation of EGFR at the plasma 
membrane further emphasizes the role of PTRPG in regulating ligandless EGFR. PTPRJ, 
unlike PTPRG, is possibly immune to the EGF triggered ROS mediated inhibition and hence 
showed a considerable effect on EGFR phosphorylation at 5 min. Like PTPN2, PTPRJ has 
a role in suppressing prolonged signaling from liganded receptors. 
3.6 PTPRG STRONGLY AFFECT ENDOSOMAL SIGNALING 
Upon interacting with pY1068 of EGFR, Grb2 interacts with other protein complexes and 
turns on a specific downstream signaling like e.g. MAPK or AKT (Gan et al., 2010). Rapid 
changes in terms of the architecture of the plasma membrane due to assembly of the proteins 
occurs upon GF stimuli.  Vesicular trafficking not only shuttles liganded and ligandless 
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receptors to different phosphatase regions or to lysosomal degradation, but it also provides 
a compartment for a sustained downstream signaling.  To determine how PTPx affect 
phosphorylation of Y1068 on the endosomal EGFR, we identified endosomes by using EGF-
Alexa 647 intensity images and extracted different measurable values for the identified 
endosomes like intensity of Alexa 568 (pY1068) and mTFP (EGFR) for each time point 
(Figure 3-15 A). The number of endosomes was normalized to the total number of cells for 
each time point. This analysis showed that upon 5P-EGF stimulation at 30 min for the 
control, there is a wide distribution of EGFR Y1068 phosphorylated endosomes that has two 
peaks. Considering, the cells were stimulated with 5P-EGF, at 30min the variation in 
endosomal EGFR phosphorylation is mainly due to mixture of low to high number of 
phosphorylated receptors per endosomes (Villaseñor et al., 2015, 2016). At 120 min, 
however, lower phosphorylation of EGFR per endosomes shows the effect of endogenous 
perinuclear PTPs (Figure 3-15 B).  
Upon ectopic expression of PTPN2, PTPRG or PTPRJ, EGFR phosphorylation on 
endosomes was highly compromised both at 30 and at 120 min (Figure 3-15 C). PTPN2 and 
PTPRJ both allow weak endosomal signaling that is evident from the skewness in 
distribution towards the left side of the plot.  PTPRG, on the other hand, is capable of 
shutting complete endosomal signaling mainly due to its own activity coupled with highly 
expressed endogenous ER-PTPs. Although this proves that PTPs play an important role in 
regulating endosomal downstream signaling, the difference in PTPRG and PTPN2/PTPRJ 
suggest that they might also regulate specific downstream signaling. 
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Figure 3- 15 A) Identification of endosomes for each timepoint by using EGF-Alexa647 
images in a python based-Segmentor tool. Distribution of the fraction of EGFR 
phosphorylated at pY1068 per endosomes for B) control at 30 min and 120 min (n~90, 
N=4) and C) upon ectopic expression of PTPX-mCitrine (n~60, N=3) (top row=30min; 
bottom row=120 min) 
 69 
DISCUSSION 
 
Ligand binding elevates the intrinsic kinase activity of EGFR, leading to phosphorylation of  
its C terminal tyrosine residues and allows binding of adaptor proteins that transduces signal 
to the downstream protein (Arkhipov et al., 2013; Kovacs et al., 2015; Schlessinger, 2002; 
Shan et al., 2012; Wagner, Stacey, Liu, & Pawson, 2013). Ligand bound EGFR at the plasma 
membrane is ubiquitinated and is internalized in vesicles that integrates with early 
endosomes maturing to late endosomes (LEs) which eventually fuse with lysosomes where 
the receptors are denatured and degraded (Bucci et al., 1992; Levkowitz et al., 1999; Rink, 
Ghigo, Kalaidzidis, & Zerial, 2005; Villaseñor, Kalaidzidis, & Zerial, 2016).  ER-PTPs like 
PTPN1 have been reported as regulators of liganded EGFR (Baumdick et al., 2015) but they 
also act on monomeric ligandless EGFR and thus facilitate EGFR to recycle back to the 
plasma membrane via Rab11-recycling endosomes.(Baumdick et al., 2015; Ullrich, Reinsch, 
Urbé, Zerial, & Parton, 1996). This report implies that the vesicular dynamics is an integral 
part in regulating EGFR activity. 
From literature, it is known that PTPRG expression is downregulated in breast cancer 
(Panagopoulos et al., 1996), nasopharyngeal carcinoma (Kwok et al., 2015) and chronic 
myeloid leukemia (Della Peruta et al., 2010). The gene expression is repressed mainly due 
to hypermethylation of CpG island in its promoter region (Della Peruta et al., 2010; Xiao et 
al., 2014). PTPRJ is frequently deleted in breast, colon and thyroid cancers (Iuliano et al., 
2004; Ruivenkamp et al., 2002). There is a study that shows PTPRJ expression is higher in 
the invasive breast cancer cells like MDA-MB-231, Hs578T and BT-549 as compared to the 
less invasive cells like MCF7, T47D, SKBR3 and MCF10A (Spring et al., 2015). ER-PTP 
like PTPN2 gene expression is low in the breast cancer cells (Shields et al., 2013). This gene 
 70 
is lost in triple negative breast cancer (Shields et al., 2013). Upon reconstituting PTPN2 
levels in these cell lines, it was observed that cell proliferation was impaired. Although SHP2 
is the only PTP that has been identified as an oncogene (Loh et al., 2003; Tartaglia et al., 
2001) there are few PTPs like PTPN1, PTPRA and PTPRF whose physiological role is 
unclear. (Nanney, Davidson, Gates, Kano, & King, 1997; Tanner et al., 1996; Yang et al., 
2005; Yip, Saha, & Chernoff, 2010) (Gu et al., 2017; Tabiti, Smith, Goh, & Pallen, 1995). 
(LeVea, McGary, Symons, & Mooney, 2000).  As most of these cell lines show an elevated 
RTK activity and have dysfunctionality in phosphatase indicates that inhibition of PTPs is 
one an important mechanism to maintain RTK signalling. Although few large-scale 
screening and many individual studies have investigated the role of PTPs in RTK signaling 
(Barr et al., 2009; Liu & Chernoff, 1997; Tarcic et al., 2009; Tiganis, Bennett, Ravichandran, 
& Tonks, 1998; Yao et al., 2017; Yuan, Wang, Zhao, & Gu, 2010), they all lack the temporal 
and spatial resolution to know ‘when’ and ‘where’ the spatially segregated PTPs acts on a 
RTK like EGFR. By using a quantitative imaging of EGFR phosphorylation, EGFR-PTP 
interactions studies and decomposing phosphorylation:dephosphurlation cycle in space, we 
identified endoplasmic reticulum (ER) associated PTPN2 and plasma membrane associated 
receptor-like PTPRG/J as strong, direct negative regulators of EGFR that along with 
vesicular machinery of a cell determine RTK functionality.  
4.1 ER-LOCALIZED PTPN2 AND PM LOCALIZED PTPRG/RJ ARE 
STRONG REGULATOR OF EGFR  
To compare the strength at which the identified PTPs act on EGFR, we measured how 
EGFR-mTFP phosphorylation profiles were affected by ectopic PTPX-mCitrine expression 
(Figure 3.6). The specific activity of each PTPs were calculated from scatter plots of the 
fraction of phosphorylated EGFR (α) against PTPX-mCitrine fluorescence intensity in each 
cell at each time point (Figure 3.5). This analysis showed that PTPN2 and PTPRG/RJ are 
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strong regulator of EGFR (Figure 3.6). As discussed earlier, the strong activity of ER-PTPs 
like PTPN2 is mainly due to their structure that higher affinity towards RTKs like EGFR 
that possesses phosphorylated tyrosine residues embedded in acidic/basic/ neutral sequences 
(Barr et al., 2009; Sarmiento et al., 2000; Selner et al., 2014). Dr Stefan Knapp lab in 
University of Oxford showed that PTPRG and PTPRJ (Barr et al., 2009) act strongly on the 
peptide that mimics the amino acid sequence of the C-terminal tail of EGFR with a pY1068 
residue. Considering the strong effect on EGFR phosphorylation was exhibited by spatially 
segregated PTPs like ER-bound PTPN2 and plasma membrane bound PTPRG/J, vesicular 
trafficking becomes an important machinery by which EGFR shuttles between plasma 
membrane and ER. These experiments were carried out with MCF7 cells ectopically 
expressing EGFR-mTFP and PTPX-mCitrine in absence of cCBL-BFP. Ectopic expression 
of cCBL is necessary for an efficient internalization of ectopically expressed EGFR-mTFP 
(Figure 3.8)(Ravid, Heidinger, Gee, Khan, & Goldkorn, 2004). This might explain why 
PTPN1, a known regulator of EGFR (Baumdick et al., 2015; Liu & Chernoff, 1997) showed 
a weak dephosphorylation activity towards EGFR at late time point. This information also 
suggests that dephosphorylation of EGFR by PTPN2 is due its fraction that extends to the 
periphery of a cell (Figure 3.6, Figure 3.11). 
4.2 PTPRG HAS AN AFFINITY TOWARDS LIGANDLESS EGFR 
By using a cell array fluorescence lifetime imaging microscopy (CA-FLIM) (Grecco et al., 
2010) and a reciprocal genetic perturbation approach we identified four classical PTPs: 
PTPN2/PTPRA/RG/RJ as non-redundant negative regulator of EGFR (Figure 1.7). In 
literature, few PTPs have been shown to affect EGFR phosphorylation like PTPN2 acts on 
SHP2 and Grb2 binding sites pY992 and pY1068 respectively (Scharl, Rudenko, & McCole, 
2010; Tiganis et al., 1998). PTPRJ /RG acts on both Grb2 binding sites - pY1068 and 
pY1086 (Kwok et al., 2015; Tarcic et al., 2009). There are also few papers that show that 
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PTPs like PTPN1 and PTPN2 directly interact with EGFR. These works, however, do not 
demonstrate the temporal changes in PTP-EGFR interaction pattern upon GF- stimulation. 
In this thesis, to understand the mechanism by which PTPs act on EGFR, we mutated the 
catalytic site of their PTP domain (Blanchetot, Chagnon, Dubé, Hallé, & Tremblay, 2005; 
Flint, Tiganis, Barford, & Tonks, 1997). These mutations stabilize the interactions between 
PTPTM and its substrate (Flint et al., 1997). As the PTPTM constructs are tagged with mCitrine 
and EGFR is tagged with mTFP, it allowed us to assess their interaction by using FRET-
FLIM (Figure 3.1). This also helped us in identifying weak and transient interactions, which 
is not possible assess by using biochemical approaches. PTPs like PTPRA/E/FG and PTPN6 
have been shown to interact with EGFR for the first time in this thesis (Figure 3.1). The 
difference in substrate interaction between ER-PTPs and R-PTP is due to their structure. The 
structural features of ER-PTPs like PTPN1 and PTPN2 show presence of amino acids like 
Arg47 that confers substrate recognition plasticity while the presence of Gly259 allows high-
affinity binding of substrates (Sarmiento et al., 2000).  These features of ER-PTPs allow 
them to interact with their substrate strongly as compared to other cytosolic or receptor like 
PTPs (Sarmiento et al., 2000). PTPRG has less preference towards liganded EGFR and more 
towards ligandless EGFR (Figure 3.1, Figure 3.11) which are predominantly in a monomeric 
state (Baumdick et al., 2015). PTPN2, on the other hand, interacted strongly at all time-
points, while PTPRJ and PTPRA showed stronger interaction only at the late time-point 
implying they regulate either recycled ligandless EGFR or internalized liganded EGFR 
(Figure 3.1). As ligandless receptors are mainly recycled to the plasma membrane while 
liganded EGFR are internalized and trafficked to the perinuclear region, it is necessary to 
spatially decompose the EGFR interaction/phosphorylation in order to understand the 
regulation of specific EGFR complexes. The STMs for the α of PTPRG indeed showed 
that it interacts with ligandless EGFR-mTFP at the plasma membrane and did not show 
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considerable change upon stimulation proving that its major role is in regulating EGFR 
responsiveness towards EGF. In the same line, an increase in interaction of PTPN2 with 
EGFR in the perinuclear region suggested an important role in regulating EGFR signaling 
at a later time-point. 
4.3 PTPN2 INCREASES RECYCLING OF EGFR TO THE PLASMA 
MEMBRANE 
The localization sequences of PTPs are important in determining their distribution in cell 
and its accessibility to substrate (Andersen et al., 2001; Tonks, 2006). Both PTPRG and 
PTPRJ showed a steep gradient in PTPx-mCitrine distribution from the plasma membrane 
to the perinuclear region while PTPN2 showed a gradual increase in its concentration. 
Ligand activated EGFR gets internalized and is distributed to the perinuclear localized Rab7 
positive late endosome during which it gets dephosphorylated by ER-PTPs (Figure 3.9). This 
unidirectional trafficking is highly dependent on ubiquitination of EGFR which in turn 
depends on phosphorylation of pY1045 (Figure 3.10)(Grovdal, Stang, Sorkin, & Madshus, 
2004).  
By affecting the pY1045 phosphorylation site in absence and presence of EGF, PTPN2 
participate in repopulating the plasma membrane with monomeric EGFR that are 
internalized by autonomous or EGF dependent activation. While by not showing 
considerable difference upon EGF stimulation, PTPRG shows to reactive specifically 
towards ligandless EGFR molecules. This observation aligns with the results of the PTPRG 
trapping mutant (Figure 3.11), emphasizing that PTPRG amongst other PTPs constitutively 
acts on the ligandless EGFR and maintain the plasma membrane population by affecting its 
internalization. 
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4.4 PTPN2 AND PTPRJ DETERMINE DURATION OF EGFR 
DOWNSTREAM SIGNAL 
The STMpY1068-norm shows a massive phosphorylation of liganded EGFR at the plasma 
membrane that gets internalized due to vesicular trafficking (Figure 3.12). As we stimulate 
with a 5min pulse of 200 ng EGF-Alexa647, we obtain a mixture of liganded and ligandless 
EGFR at later time points. The ligandless monomeric EGFR is dephosphorylated by 
endogenous ER-PTPs and is recycled back to the plasma membrane where it is reactivated 
due to autocatalytic activity of other active ligandless EGFR(Baumdick et al., 2015).  
Whereas liganded, dimeric EGFR unidirectional traffics to late endosomes where it gets 
inactivated by dephosphorylation before degradation (Figure 3.9 and Figure 3.11)(Baumdick 
et al., 2015). To learn how PTPs on juxtaposed membranes affect EGFR signaling from 
ligandless monomeric and liganded dimeric EGFR, we calculated the phosphorylation fold 
change (PFC) of cells with ectopic PTPX expression (PFC-cDNA PTPX) and of cells with 
siRNA mediated knock-down (PFC-siRNA PTPX) from EGFRpY1068 immunofluorescence 
experiments (Figure 3.14). These PFC profiles showed that PTPRG and PTPRJ strongly 
affected signaling from ligandless EGFR at the plasma membrane while PTPN2 acted on 
liganded internalized EGFR molecules, implying its role in determining signal duration. 
PTPRG affected overall endosomal phosphorylation (Figure 3.15) which it can achieve only 
in association with endogenous perinuclear PTPs like PTPN1 and PTPN2. Both PTPRG and 
PTPN2 acted on signaling from monomeric EGFR before EGF stimulation, proving that 
these PTPs collaboratively regulate any spurious signal occurred due to autonomous 
activation of EGFR. Weak activity of PTPRG as compared to PTPRJ at early stimulation 
time-point suggests an underlying inhibitory biochemical regulation that affect PTPRG and 
not PTPRJ. Through other experiments performed in the department, we know that EGF-
 75 
mediated ROS generation oxidizes the catalytic cysteine in PTPRG which leads into its 
inactivation at early time point.  
In summary, the negative regulation of PTPRJ and PTPN2 to EGFR assist in dampening 
prolonged signaling from the plasma membrane and the perinuclear region. The reactive 
oxygen mediated toggle switch between EGFR and PTPRG at the plasma membrane avails 
resistance to cells from massive EGFR signaling at low dose of EGF present in the media. 
By recycling ligandless EGFR after PTPN2 mediated dephosphorylation the vesicular 
trafficking machinery couples a EGFR-PTPN2 negative feedback to a EGFR-PTPRG toggle 
switch into a spatially organized network. This network architecture allows the cells to 
sample their environment for growth factors, to responds at specific doses and to allow 
downstream signaling in order to determine cell fate. 
  
Figure 4. 1 Scheme of the EGFR-PTP interaction network established through EGFR trafficking 
dynamics. EGFR interacts with PTPRG at the PM and with PTPN2 in the cytoplasm. EGFR 
trafficking dynamics: ligandless EGFR recycles via early (EE) and recycling endosomes (RE) 
to the PM (red arrows) whereas upon EGF binding (thin green arrow), ubiquitinated EGF-
EGFRUb unidirectional trafficks via the early- to the late endosomes (LE, green arrow) to be 
degraded (∅). Causal links are denoted with solid black lines. 
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